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Jason Jae-Hyuk Kwon 
PATHOPHYSIOLOGICAL ROLE OF MICRORNA-29  
IN PANCREATIC DUCTAL ADENOCARCINOMA 
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy and 
responds poorly to current therapies. Thus, it is imperative to develop novel treatments 
for PDAC. Dense fibrotic stroma associated with PDAC abrogates drug perfusion into 
the tumor, and pancreatic stellate cells (PSCs) are the major stromal cells responsible for 
fibrosis. Activated PSCs produce pro-inflammatory factors and secrete an excessive 
amount of extracellular matrix (ECM) proteins, the major stromal proteins in PDAC.  
MicroRNAs (miRNAs) are conserved small non-coding RNAs that regulate gene 
expression by binding to the 3′UTR of target mRNA transcripts, causing translational 
repression or degradation. A single miRNA regulates several targets within intracellular 
networks and can have a profound impact on normal physiology.  
miR-29 has been previously reported to have anti-fibrotic and tumor suppressive 
roles in various cancers. We found miR-29 expression was significantly decreased in 
activated PSCs and pancreatic cancer cells in vitro, in vivo models, as well as in PDAC 
patient biopsies. Through in vitro studies in activated PSC, we found that miR-29 
inhibited the expression of ECM proteins and reduced cancer growth when co-cultured 
with pancreatic cancer cells. miR-29 overexpression in pancreatic cancer cells decreased 
their invasive potential and sensitized chemoresistant cancer cells to gemcitabine 
treatment by inhibiting autophagy through the direct targeting of two essential, autophagy 
related genes, TFEB and ATG9A.  
vii 
In developing therapies and for in vivo functional studies, viral-based gene 
delivery is a powerful tool to target the pancreas. We tested various self-complementary 
recombinant adeno-associated virus (scAAV) serotypes in normal mice (C57BL/6) and in 
a KrasG12D-driven pancreatic cancer mouse model via systemic and intraductal delivery 
methods. We found that retrograde intraductal delivery of scAAV6 safely targeted the 
pancreas/neoplasm with the greatest efficiency.   
Our findings provide a better understanding of miR-29 in pancreatic cancer and 
demonstrates its potential therapeutic use to target PDAC.  
 
 
Janaiah Kota, Ph.D., Chair 
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Chapter 1: Introduction 
1.1 The Current State of Pancreatic Cancer: Prognosis and Treatment Strategies 
Pancreatic cancer is one of the leading causes of cancer deaths in western 
societies, with the worst prognosis (1). In the United States, it is the third leading cause of 
cancer deaths, and projected to become the second leading cause of cancer related deaths 
in just over a decade (2). Pancreatic cancer originates from exocrine cells of the pancreas, 
and among all exocrine tumors, PDAC is the most common type of pancreatic neoplasm, 
accounting for more than 90% of pancreatic tumors (3). In spite of intense research 
efforts and the development of numerous new cancer drugs and treatment strategies over 
the past four decades, there has been no significant improvement in overall patient 
survival for pancreatic cancer  and death rates are almost equivalent to incidence rates 
(4). 
Surgery, radiation, and chemotherapy are treatment options that may extend 
patient survival or reduce symptoms, but they seldom produce a cure. Surgical resection 
or surgery in combination with adjuvant therapy is the only potentially curative therapy 
that improves overall patient survival (5). However, only a minority of PDAC patients 
are candidates for surgery due to the typical timing of diagnosis at late stages of 
progression, where the cancer has metastasized to other parts of the body, and the tumors 
are not amenable to current therapeutic modalities (6, 7).  
For the past several decades, gemcitabine (difluorodeoxycytidine) has remained 
the standard of care for chemotherapy of pancreatic cancer. Gemcitabine is a cytotoxic 
nucleoside analog that is phosphorylated within the cell by deoxycytidine kinase (8), and 
the reaction product then competes with endogenous cytosine triphosphate during DNA 
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synthesis (9). Once incorporated into the synthesizing strand of DNA, masked chain 
termination is induced, triggering apoptosis (9).  In recent years, combination treatments 
involving folinic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) or 
Gemcitabine/Nab-paclitaxel have received FDA approval for pancreatic cancer, but these 
therapies may be associated with severe toxicity issues and each only modestly improve 
patient survival (10). Unfortunately recent improvements in combination chemotherapy 
and patient selection for targeted therapies have moderately improved outcomes for 
PDAC patients, with an average overall 5-year survival rate of less than 8% (11).  
Overall, pancreatic cancer is still refractory to most therapeutic strategies. Therefore, a 
better understanding of the mechanistic underpinnings of pancreatic cancer is needed to 
generate new strategies for more effective treatments. 
 
1.2 Tumor Stroma and its Role in PDAC Progression  
Dense fibrotic stromal reaction, called desmoplasia, is a histopathological 
hallmark of PDAC.  The stroma surrounding pancreatic cancer cells is composed of both 
cellular (e.g. pancreatic stellate cells, fibroblasts, vascular, and immune cells) and 
acellular (e.g. extracellular matrix [ECM] proteins, cytokines, and growth factors) 
components (12, 13) (Figure 1). Dynamic interactions between stromal components and 
pancreatic cancer cells is an integral part of PDAC progression and metastasis.  
In the normal pancreas, a resident subclass of fibroblasts, consisting of pancreatic 
stellate cells (PSCs), immune cells, and vascular cells, play a critical role in tissue repair 
and wound healing. In response to pancreatic tissue damage, injured acinar cells secrete 
pro-inflammatory and pro-angiogenic growth factors/cytokines, and induced immune 
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cells, PSCs/fibroblasts, and endothelial cells to engage immune surveillance, synthesize 
connective tissue, and generate blood vessels, respectively, which collectively restore 
normal pancreatic function (14). However, chronic inflammatory responses involving 
pancreatic cancer cells have been known to alter the properties of PSCs, immune cells, 
and vascular cells, creating a favorable microenvironment for tumor progression (14, 15).   
  In the PDAC tumor microenvironment, cancer cells secrete pro-inflammatory 
growth factors/cytokines, including TGF-β1, PDGF, TNFα, and IL-1/6, that activate 
PSCs and pancreatic fibroblasts. Activated PSCs/fibroblasts transform into a 
myofibroblast-like cells that secrete large amounts of extracellular matrix (ECM) 
proteins, comprised of collagens, fibronectins, and laminins, that form fibrous tissues 
situated in the periacinar regions of the organ (16, 17). Furthermore, activated 
PSCs/fibroblasts produce pro-inflammatory growth factors/chemokines that act in an 
autocrine fashion to maintain their sustained stimulation, leading to the production of 
fibrotic stromal ECM proteins (18, 19) (Figure 1). Excessive ECM deposition in 
periacinar regions distorts normal parenchyma, causing compression of the vasculature 
that leads to hypovascularity and hypoxia in the tumors (20, 21). Tumor hypoxia is also 
known to activate PSCs that maintain and perpetuate the hypoxia-fibrosis cycle (22). In 
addition, dense fibrotic stroma causes dysfunctions in the vasculature, impairing drug 
delivery to the cancer cells that as a consequence reduce therapeutic efficacy (21). 
Pancreatic cancer cells also suppress tumor immune surveillance by decreasing cytotoxic 
CD8 T cells and increasing the presence of immunosuppressive macrophages (M2), 
neutrophils (N2), and T-regulatory cells (Th2) (23, 24). Dense fibrotic stroma, in 
combination with immune suppression and neo-angiogenesis, creates a more favorable 
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environment for pancreatic cancer progression and metastasis (25). PSCs are also known 
to closely interact with pancreatic cancer cells to promote metastasis and have even been 
shown to co-migrate to distant metastatic sites, establishing stromal abundant tumors 
beyond the pancreas (26-28).  
Developing therapies for advanced PDAC is much more complicated than simply 
targeting pancreatic cancer cells, as the associated tumor stroma plays an important role 
in progression, drug resistance, and metastasis (20, 21).  In fact, stromal biology and 
targeted therapies are currently under intense investigation in an attempt to improve the 
efficacy of chemotherapy and patient survival. Tuveson and colleagues were one of the 
first to report the therapeutic efficacy of targeting stroma in pancreatic cancer (21). 
Utilizing a small molecule inhibitor of smoothened (Smo)  (IPI-926) to inhibit hedgehog 
pathway and lead to stromal ablation, gemcitabine treatment in combination with IPI-926 
led to a significant increase in intratumoral vascularization, drug perfusion, and overall 
survival in a genetically engineered mouse model of pancreatic cancer (21). Similar 
results were observed with various other similar anti-stromal approaches in PDAC pre-
clinical settings, such as utilizing enzyme-based ECM protein depletion strategy by 
targeting hyaluronan via PEGylated recombinant hyaluronidase (PEGPH20) (29-31) or 
treating with anti-fibrotic drug pirfenidone (32, 33).  
Based on these findings, IPI-926 was tested in combination with gemcitabine in 
PDAC clinical trials. Unfortunately, long-term Phase II/III clinical trials not only failed to 
show treatment benefit, the IPI-926/gemcitabine combination cohort actually fared worse 
than the cohort that received gemcitabine alone (34). In contradiction to previous reports, 
recent paradoxical evidence suggests that pancreatic stroma acts to restrain tumor growth, 
5 
not promote it (35, 36). Two independent research groups depleted the stroma through 
different means in PDAC mice using genetic (thymidine kinase mediated PSC depletion) 
or pharmacological (IPI-926) approaches and found that stromal ablation induces a de-
differentiated cancer phenotype, enhances disease progression, and reduces survival (35, 
36). However within the same year, Ronald Evan’s group demonstrated that a more 
subtle approach of reverting activated PSCs to quiescence led to a more promising 
therapeutic approach in contrast to complete stromal ablation (37). Treatment with 
vitamin D analog, calcipotriol (Cal) in combination with gemcitabine administration 
reprogrammed PSCs to a less fibrotic/inflammatory state that enhanced drug efficacy and 
improved survival of genetically engineered mouse models of PDAC (37). Based on 
these preclinical studies, this novel stromal reprogramming therapeutic strategy is 
currently being evaluated in PDAC patients with advanced disease in combination with 
PD1 Inhibitor, Pembrolizumab (ClinicalTrials.gov; NCT03331562).  
The culmination of these studies indicates that PDAC stroma is a heterogeneous 
and complex tissue, and different components of the stroma potentially have diverse roles 
that can promote or inhibit tumor growth. Given the failure of stromal ablation 
therapeutic strategies in clinic and the potential of the stroma to restrain tumor growth, 
efforts are now focused on developing novel stromal-targeted therapies that appropriately 
modulate the stroma and avoid the extremes of ablation versus abundance (25, 37).  
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Figure 1. Pathogenesis of Pancreatic Cancer and its Associated Stroma   Illustration 
of the progression of PDAC from normal pancreatic duct to precursor pancreatic 
intraepithelial neoplasm (PanIN) and ultimately to invasive/metastatic cancer (left to 
right). During carcinogenesis, normal ductal epithelial cells (tan cells) acquire oncogenic 
mutations (e.g. Kras) (light orange cells) early and develop into hyperplastic ductal 
lesions called PanIN which progress through various grades (PanIN-1A, PanIN-2A, 
PanIN-2, and PanIN-3), eventually developing into fully invasive and metastatic 
pancreatic cancer (dark brown cells). Pancreatic cancer cells (dark brown) and pancreatic 
stellate cells (blue) release TGF-β1 and other pro-inflammatory cytokines/growth factors 
that activate pancreatic stellate cells to produce ECM proteins and increase fibrotic 
stromal deposition. A close interaction between stellate cells, cancer cells, and pro-
inflammatory growth factors/cytokines contribute to the PDAC progression and 
metastasis. 
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1.3 Autophagy in Pancreatic Cancer 
Dense fibrotic PDAC stroma with poor intratumoral vasculature leads to a 
nutrient deprived, hypoxic tumor microenvironment (38). Under these harsh conditions, 
pancreatic cancer cells induce macroautophagy (autophagy) as a survival mechanism to 
maintain energy homeostasis, proliferation, and metastasis (39-41). Autophagy is the 
process in which cytosolic components are enveloped by double-membrane vesicles 
called autophagosomes that are trafficked to the lysosome for degradation/recycling (42).   
Autophagy is initiated at phagophore assembly sites (PAS) on the endoplasmic 
reticulum (ER) (43-45) where the UNC51-like kinase (ULK) complex is recruited, 
consisting of ULK1, ATG13, FIP200, and ATG101 (46). This initiating event leads to the 
budding and elongation of a double membrane structure as ULK1 phosphorylates and 
activates Beclin 1 (47), which is a part of the class III PI3K complex along with ATG14, 
VPS15, and VPS34 (48). The activated class III PI3K complex converts 
phosphatidylinositol 2-phosphate (PIP2) to phosphatidylinositol 3-phosphate (PIP3), and 
PIP3 accumulation recruits WD-repeat protein interacting with phosphoinositides (WIPI) 
proteins (49). WIPI proteins recruit the ATG12/ATG5/ATG16 complex (50) which is 
required for the critical step of lipidating microtubule-associated protein 1 light chain 3 
(LC3) to phosphatidylethanolamine on the phagophore membrane in an E3 ubiquitin 
ligase-like manner (51). Subsequently, sequestosome-1 (SQSTM1/p62), which binds to 
polyubiquitinated substrates, recruits cargo to the autophagosome by binding to lipidated 
LC3B to be degraded (52). The phagophore eventually encloses around the cargo and is 
referred to as an autophagosome. Autophagosomes are then trafficked to the lysosome, 
and once autophagosomes fuse with lysosomes, the hydrolases of the lysosomal 
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compartments degrade the internal substrates of the autophagosomes and release the 
basic cellular building blocks into the cytosol for recycling (42).  
Recent studies document that the upregulation of autophagy can serve as a 
survival mechanism in various malignancies (53-61) including PDAC tumor growth and 
progression (39-41). Furthermore, autophagy inhibition was shown to potently sensitize 
pancreatic cancer cells to gemcitabine treatment (39) and increased survival (40).  As a 
consequence, autophagy has become a therapeutic target of PDAC, and clinical trials are 
currently underway testing the therapeutic efficacy of lysosomotropic agent 
hydroxychloroquine (HCQ) as an autophagy inhibitor in combination with gemcitabine to 
target PDAC (ClinicalTrials.gov; NCT01506973 & NCT01978184). However, HCQ has 
been known to exhibit off-target effects and toxicity in a wide variety of diseases in 
clinical studies (62-65), suggesting a great need to understand the molecular mechanisms 
associated with PDAC autophagy and to develop alternative therapies that are safe and 
effective to target autophagy. 
 
1.4 miRNA Biology and the miR-29 Family 
miRNA are small non-coding RNAs, approximately ~20-30 nucleotides in length, 
and are known as powerful regulators of gene expression in eukaryotes. Since the first 
miRNA, lin-4, was reported by Ambros in 1993 (66), the field of miRNA biology has 
exploded as revelations were made that these minute RNAs had implications in a 
multitude of physiological processes and diseases.  
miRNAs are normally transcribed as long transcripts by RNA polymerase II and 
are commonly embedded in the introns and exons of both coding and non-coding genes 
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(67). Within these long transcripts, they form a characteristic hairpin structure and are 
referred to as primary miRNAs (pri-miRNAs) (67). Subsequently, pri-miRNAs are 
processed by ribonuclease enzyme Drosha, which cleaves at the base of the hairpin (68). 
The liberated hairpin is referred to as precursor miRNA (pre-miRNA) which is exported 
out of the nucleus by exportin 5 (69) and further processed in the cytoplasm by another 
endonuclease, Dicer, to yield a double stranded mature miRNA (70). Finally, one of the 
strands of mature miRNA is loaded onto the Argonaut proteins (AGOs) to form the RNA 
induced silencing complex known as RISC (71). Following its association within RISC, 
miRNAs function through a 6-8mer sequence known as a seed sequence that binds to 
complementary sequences in the 3’ untranslated region (UTR) of target mRNAs through 
canonical Watson-Crick base pairing, leading to repression of expression (67).  
Several miRNAs have common seed sequences and have been known to regulate 
a similar repertoire of target transcripts. Accordingly, evolutionarily conserved miRNAs 
sharing analogous seed sequences have been organized into 87 distinct miRNA families 
(72). As one of these miRNA families, miR-29 consists of three paralogous members, 
miR-29a, miR-29b, and miR-29c. miR-29a and -29b-1 are encoded on chromosome 
7q32.3, known as the miR-29a/b-1 cluster, and miR-29b-2 and -29c are found on 
chromosome1q32.2, designated as the miR-29c/b-2 cluster. While all three family 
members share a common 7nt seed sequence, there are reports of unique 
sequence/functional features of each miR-29 family member (Figure 2).  
One of the notable differences among miR-29 family members resides within a 6 
nucleotide segment that is unique to miR-29b (Figure 2). This hexanucleotide sequence 
present in nucleotide positions 18-23 has been functionally shown to lead to miR-29b 
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nuclear localization (73). In fact, the simple addition of the miR-29b nuclear localization 
sequence (NLS) to the 3’end of siRNAs was found to be sufficient to cause nuclear 
localization (73). Consistently, another report evaluating the therapeutic efficacy of miR-
29b in targeting a subunit of the proteasome found that the deletion of the hexanucleotide 
NLS lead to cytoplasmic enrichment of miR-29b and further enhanced the 
downregulation of the target transcript (74). Although miR-29b’s function within the 
nucleus has yet to be fully elucidated, this research has opened the gates to the discovery 
of \ other miRNAs that similarly localize to the nucleus to elicit non-canonical functions 
beyond binding to the 3’-UTR of mRNA transcripts in the cytoplasm (75, 76). 
Elucidating the role of miRNAs in the nucleus is still an active and ongoing area of 
research. There have been reports in which miRNAs regulate gene expression in the 
nucleus by inducing epigenetic changes (77) as well as through direct binding to the 
transcription start sites of genes to inhibit its transcription (78). A number of reviews are 
available on this subject matter (79, 80), but for simplicity, we will focus on the 
canonical/cytoplasmic function of miR-29 for the remainder of the thesis.  
In addition to the hexanucleutide sequence, miR-29a has a distinct cytosine 
residue at position 10 (Figure 2). This difference is of particular importance as uracil 
residues located in nucleotide positions 9-11 of miRNAs have been found to have rapid 
decay/turnover (81). This tri-uracil sequence is found in both miR-29b and miR-29c, 
whereas the cytosine residue at nucleotide position 10 of miR-29a lends to its greater 
stability (81). This is consistent with pulse-chase experiments of synthetic miR-29a and -
29b in HeLa cells demonstrated a longer half-life of miR-29a compared to -29b (74) as 
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well as numerous findings that miR-29a is the most abundantly expressed family member 
(82-85).  
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Figure 2. Schematic representation of the miR-29 family members: miR-29a, -29b, 
and -29c. miR-29 family members have identical seed sequences (orange box and 
underlined) along with similar mature miRNA sequences. However notable differences in 
nucleotides are indicated in red. Tri-uracil nucleotides at positions 9-11nt (blue box) 
present in miR-29b and -29c contribute to instability and shorter half-life, and the 
hexanucleotide sequence at positions 18-23nt (green box) is unique to miR-29b, leading 
to nuclear localization. 
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1.5 In Vivo Function of miR-29 
A single miRNA family has been known to have on average >400 target 
transcripts that have matching, evolutionarily conserved 3’-UTR binding sites (86). 
Furthermore, >60% of translated genes in the human genome possess at least one miRNA 
binding site. Therefore, it is likely that the dysregulation of even a single miRNA can 
profoundly impact normal physiological processes and lead to disease. In fact, a number 
of in vivo studies in murine models have demonstrated the essential role of miR-29 in 
development and general physiology. Whole-body miR-29 knockout (KO) mice have a 
wide range of developmental defects such as premature thymic involution (87), muscle 
wasting (88), growth retardation, and shorter lifespan (89). In addition, liver-specific 
miR-29 KO mice had a robust increase in hepatic fibrosis and carcinogenesis (90) 
implicating its physiological relevance. 
 A recent report profiled miR-29a and miR-29c function in the pancreata of whole-
body KO mouse models in the context of glucose regulation and diabetes (84). miR-29a 
KO mice had a defect in insulin secretion but interestingly, miR-29c KO mice did not 
(84). Similarly, miR-29a KO in an insulitis transgenic model (insHEL) resulted in 
diabetes, whereas wildtype (WT) mice did not (84). Taken together, miR-29a plays a 
vital role in proper pancreatic function and elicits a protective effect against diabetes in 
the context of insulitis (84). With these studies in mind, it is no surprise that miR-29 has a 
profound impact on cancer biology as well. 
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1.6 Statement of Purpose 
In the context of cancer pathogenesis, miR-15a/miR-16 was the first miRNA 
cluster found to be aberrantly regulated, with a documented deletion of the encoding 
genomic region reported in chronic lymphocytic leukemia (91). Since then, dysregulated 
miRNA signatures have become a well-established feature of various cancers. Among 
dozens of miRNAs reported to be abnormally expressed in cancer, miR-29 has been 
recognized as one of the critical miRNAs that play a role in cancer pathogenesis.   
There is a vital need for identifying novel mechanisms of PDAC fibrosis in order 
to develop more effective therapeutic targets that will modulate the stroma with more 
subtle approaches without complete ablation. miR-29 has been shown to suppress the 
fibrosis of various organs such as heart (92), liver (93), lung (94), kidney (95), and 
muscle (96), by reducing ECM deposition and inflammation. However, the role of miR-
29 in the context of pancreatic fibrosis had not been established. Thus, we sought to 
establish miR-29’s function in PSCs, the major stromal cells in PDAC stroma, to test its 
anti-fibrotic potential.  
In addition to miR-29’s role in fibrosis, a comprehensive survey of the current 
research work on miR-29 in cancer reveals a large body of literature reporting a 
significant role of miR-29 in numerous neoplastic contexts (Figure 3A). The majority of 
these studies have reported that miR-29 functions as a potent tumor suppressor. However, 
a few reports have found miR-29 to be oncogenic (Figure 3B). Therefore, additional 
studies are needed to better understand mechanisms of miR-29 in cancer, including 
pancreatic cancer. Furthermore, as current therapies for PDAC are ineffective in 
significantly improving overall survival (10), novel therapeutic options are desperately 
15 
needed. In view of miR-29’s tumor suppressor function in various cancers, we tested its 
therapeutic effects in pancreatic cancer cells.  
Here in this thesis, we sought to establish the pathophysiological role of miR-29 
in PDAC. First, we investigated miR-29 expression levels in a murine model of 
pancreatic cancer and PDAC patient biopsies, as well as determined its functional effect 
in PSCs. Second, we went on to establish miR-29’s role as a tumor suppressor in 
pancreatic cancer cells and identified a novel role of miR-29 in regulating PDAC 
autophagy. Lastly, we optimized a pancreas-specific gene delivery technique for murine 
models in order to provide an auspicious approach for future functional studies of miR-29 
in vivo. Each of these studies have been organized into independent chapters which 
include a brief introduction to highlight the key information germane to the chapter, as 
well as respective methods, results, and succinct discussion sections. In this way, each 
chapter can be read independently with a better appreciation of key concepts for each 
subject matter. 
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Figure 3. miR-29 studies in cancer pathogenesis.  
A compilation of primary research articles (non-biomarker based) related to miR-29 in 
the context of cancer was carried out in order to gain insight on the role of miR-29 among 
cancers. (A) The bar graph indicates the number of current publications based on cancer 
type, with Miscellaneous (Misc) indicating studies that investigate miR-29 in a broader, 
multi-cancer context. (B) Pie chart with number of publications demonstrating miR-29 as 
a tumor suppressor (green), oncogenic (red), and no effect (grey).  
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Chapter 2: Pathophysiological role of microRNA-29 in pancreatic cancer stroma 
2.1 Introduction 
PDAC is the most lethal human cancer, with a 5-year survival rate of 6% (97) and 
is projected to be the second leading cause of cancer related death by 2030 (2). Dense 
fibrotic stroma associated with PDAC tumors is a major obstacle for drug delivery to the 
tumor bed (21, 98) and plays a crucial role in pancreatic cancer progression (26, 99, 100). 
Current, anti-stromal therapies have failed to improve tumor response to chemotherapy 
and patient survival (101), and they are often associated with toxicity (34). Furthermore, 
recent studies show that the stroma impedes tumor growth, and its complete inhibition 
accelerated PDAC progression (35, 36). However, reprogramming the reactive stroma 
through modulation of a key transcriptional regulator in stromal cells suppressed the 
reactive stroma and increased tumor response to chemotherapy and survival (37). These 
studies reinforce the critical need to understand the molecular mechanisms associated 
with tumor-stromal interactions for developing effective therapeutic strategies to reduce 
PDAC mortality.  
Stroma associated with PDAC tumors is comprised of activated stellate 
cells/fibroblasts, immune cells, extracellular matrix, and pro-inflammatory 
cytokines/growth factors (12) (Figure 1). A dynamic interaction between tumor-stromal 
cells and the extracellular matrix has been shown to play a critical role in PDAC 
progression (12). A growing body of evidence suggests that PSCs are the major stromal 
cells responsible for fibrotic stroma. In normal pancreas, PSCs are located in the 
periacinar spaces and remain quiescent. In response to pancreatic injury or 
carcinogenesis, PSCs are activated by a number of pro-inflammatory growth factors and 
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cytokines, including TGF-β1, released by cancer cells, injured acinar cells (paracrine), 
and PSCs (autocrine). TGF-β1 serves as a key activator of quiescent PSCs, which is 
highly expressed in PDAC tumors and is known to play an important role in the fibrotic 
process associated with pancreatitis and PDAC pathogenesis (102, 103).  Activated PSCs 
are transformed into a myofibroblast-like phenotype and secrete excessive amounts of 
ECM proteins such as collagen, laminin, and fibronectin, a prominent component of 
PDAC stroma (104). Extensive ECM deposition causes hypovascularity in PDAC tumors 
and attenuates drug delivery to the peritumoral milieu (14). Furthermore, PSCs closely 
interact with cancer cells and the ECM to promote primary tumor growth and distant 
metastasis (26-28, 105). However, the molecular mechanisms associated with stellate-
cancer interactions remain poorly understood.  
miRNAs are conserved, non-coding RNAs that regulate eukaryotic gene 
expression and are critical in maintaining cellular homeostasis (106). A single miRNA 
regulates hundreds of genes, often targeting multiple components of complex intra-
cellular networks (107). Thus, misregulation of an individual miRNA can have a 
profound impact on cellular physiology that leads to disease(s) (108). miR-29 is known to 
play a paramount role in the fibrotic process of several organs (90, 93-96) and provide 
crucial functions downstream of pro-fibrotic signaling pathways such as TGF-β1 (109).  
Numerous functional studies have documented the anti-fibrotic activity of miR-29 in 
different tissues(110), and its restored expression reduced fibrosis by targeting ECM 
proteins(92), such as collagen and laminin. Additionally, a growing body of evidence 
implicates the role of miR-29 in cancer pathogenesis (111) and in the tumor 
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microenvironment (112). The role of miR-29 in pancreatic fibrosis and PDAC tumor-
stromal interactions however, has yet to be delineated.  
 Here in this chapter, we show that the loss of miR-29a and b is a common feature 
of activated PSCs and fibroblasts and is associated with a significant increase in stromal 
ECM deposition in vitro and in vivo. Our in vitro miR-29 gain/loss-of-function studies 
directly document the role of miR-29 in PSC-mediated stromal accumulation. In addition, 
ectopic overexpression of miR-29a or b in PSCs decreased the stroma deposition, cancer 
cell viability, and colony growth when co-cultured with pancreatic cancer cells. Our 
findings show that miR-29 plays a critical role in regulating tumor stromal deposition and 
cancer growth, thus raising the possibility that modulation of miR-29 expression in PSCs 
may be therapeutically beneficial to normalize the reactive stroma and enhance the 
efficacy of chemotherapy to target PDAC. 
 
2.2 Materials and Methods 
Mice 
 KrasG12D; Pdx1-Cre (KC) mice were generated as described (113). Conditional 
LSL-KrasG12D mice were crossed with Pdx1-Cre animals to generate the KC mice. All 
animal housing, use, and surgical procedures were carried out in accordance with the 
regulatory guidelines set by Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health.  All animal protocols were reviewed and approved by the 
Indiana University (IU) Animal Care and Use Committee. 
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Cell lines 
Immortalized mouse pancreatic stellate (mPSC) cell lines (114) were a gift from 
Dr. Raul Urrutia at Mayo Clinic, Rochester, Minnesota. Primary human PSCs were 
obtained from ScienCell Research Laboratories (Carlsbad, California), grown routinely in 
Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, 11965-092) 
supplemented with 10% fetal bovine serum (FBS), 100units ml-1 penicillin, and 100mg 
ml-1 streptomycin.  Primary human fibroblasts were purchased from Vitra Biopharma 
(Golden, CO), and were routinely cultured in their recommended media (VitroPlusII). 
Primary cancer associated fibroblasts (CAFs) isolated from PDAC patients were 
confirmed by α-SMA staining and authentication was performed by IDEXX-Radil 
(Columbia, MO). CAFs were maintained in DMEM/F-12, GlutaMAX Supplement (Life 
Technologies, 10565-018) plus 10% FBS, 100 units ml-1 penicillin, and 100mg ml-1 
streptomycin. All primary cell lines were studied prior to reaching seven passages.  
Human pancreatic carcinoma cell lines Panc-1 and MIA PaCa-2 were gifts from Karen E. 
Pollok of Indiana University School of Medicine and IU Simon Cancer Center.  Both 
were grown routinely in DMEM supplemented with 10% FBS, 100units ml-1 penicillin, 
and 100mg ml-1 streptomycin.   
Patient Tissue Procurement.  
This study was reviewed and approved by the Indiana University-Purdue 
University Indianapolis (IUPUI) Institutional Review Board (IRB) at Indianapolis, IN, 
USA (IUPUI IRB# 1303011057). Tissue biopsies and associated clinical data were 
obtained from IU Simon Cancer Tissue Bank and IU Department of Pathology. Both IU 
Simon Cancer Tissue Bank and IU Department of Pathology procured tissue samples and 
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informed consent was obtained from human subjects in compliance with IUPUI IRB 
policies. IUPUI IRB is accredited by the Association for the Accreditation of Human 
Research Protection Programs (AAHRPP). Quality and integrity of paraffin embedded or 
fresh pancreatic tissue biopsies was analyzed by a certified pathologist with hematoxylin 
and eosin staining. Control samples that were biopsied from patients with conditions 
unrelated to pancreatic disease or from an unaffected area of the pancreas from patients 
with pancreatitis were confirmed via histopathological analysis.  
RNA Extractions 
 Total RNA was extracted from formalin fixed paraffin embedded (FFPE) tissue 
samples (two 10 µm thick sections) using the MagMaxTM FFPE total nucleic acid 
isolation kit (Ambion, Life Technologies, 4463365) or from frozen tissues using Rino 
BulletBlender beads (MidSci, CAP329) followed by Trizol (Life Technologies, 
15596018) extraction. RNA was extracted from cells in vitro by Trizol extraction 
according to the manufacturer’s protocols. The quantity and purity of RNA was 
determined by OD260/280 reading using a Nanodrop spectrophotometer.   
qPCR analysis.   
Mature miR-29 family member expression levels were measured by TaqMan 
MicroRNA Assays (Applied Biosystems) for miR-29a (ID:002112); miR-29b 
(ID:000413); and miR-29c (ID:000587). U6 snRNA (ID:001973) was used as a reference 
gene to normalize the relative amount of miRNA, and samples were analyzed using ABI 
7500 real time PCR machine.  Alpha smooth muscle actin (α-SMA), connective tissue 
growth factor (CTGF), collagen 1a1 (COL1A1), laminin (LAMC1), and fibronectin 
(FN1) levels were measured using gene specific qPCR primer probes purchased from 
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Solaris Probes. RNA samples were reverse transcribed using random primers, and α-
SMA (AX-061937-00-0100); CTGF (AX-040018-00-0100); COL1A1 (AX-042068-00-
0100); LAMC1 (AX-043874-00-0100); and FN1 (AX-043446-00-0100) expression 
levels were measured using cyclophilin B (PPIB) (AX-048843-00-0100) as an internal 
control.  Samples were run in triplicates with 0.2 thresholds, and the ΔΔCT method was 
used for relative expression analysis. For miR-29 expression analysis in PDAC patient 
tumors, total RNA was isolated from FFPE tissue sections (two 10 µm) of normal 
controls (n=10) or PDAC patient tumors (n=15) with 35-80% stroma and miR-29 family 
expression was analyzed by qPCR as described above.   
Immunoblotting  
mPSCs and hPSCs were lysed in lysis buffer (50mM Hepes, 150 mM NaCl, 10% 
glycerol, 1% Triton-X, 1.5 mM MgCl2, 1 mM EGTA, 100mM NaF, 10 mM NaPPi, Na O 
Vanidate, ZnCl2, PMSF, protease inhibitor) and protein samples were ran through SDS-
PAGE.  Proteins were transferred to polyvinylidene fluoride membrane (PVDF), blocked 
in 10% dried non-fat milk, and subsequently probed with antibodies against collagen 
1alpha1 (Santa Cruz, sc-8784-R, 1:500), collagen 3alpha1 (Santa Cruz, sc-8781, 1:500), 
laminin gamma-1 (Santa Cruz, sc-5584, 1:5000), fibronectin (Santa Cruz, sc-9068, 
1:500), α-tubulin (Calbiochem, CP06, 1:3000), GAPDH (Millipore, MAB374, 1:10,000), 
and β-actin (Santa Cruz, sc-47778, 1:2000), using corresponding HRP conjugated goat 
anti-rabbit (Santa Cruz, sc-2004), goat anti-mouse (Santa Cruz, sc-2005), or donkey anti-
goat (Santa Cruz, sc-2020) secondary antibodies.  Proteins were visualized and quantified 
using chemiluminescent detection (GE Healthcare, Amersham ECL) and exposure to x-
ray film (Thermo Scientific, CL-X Posure Film). The intensity for each band was 
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densitometrically quantified and normalized against loading control using ImageJ 
software. 
Transfection 
Exponentially growing mPSCs or hPSCs were seeded in 6 well plates at 1x105 
cells per well, serum starved for 24 hours, and treated with 10 ng/ml of TGF-β1 for 24hrs 
before or after transfection with 20 nM mimics using DharmaFECT®1 (Life 
Technologies, T-2001-01) per their protocol.  For immunoblotting, cells were either 
transfected with 20 nM mimic control (Life Technologies, CN-001000-01), mimic-29a 
(Life Technologies, C-300520-05), or mimic-29b (Life Technologies, C-300520-05). For 
LNA transfection, 1x105 serum starved and TGF-β1 treated hPSCs were transfected with 
50 nM of LNA-29 (Exiqon, 450039) or LNA-control (Exiqon, 199006) using 
DharmaFECT®1. 24 hours post-transfection, protein was harvested and proteins in lysates 
were separated by gel electrophoresis and analyzed by western blot using the following 
antibodies: collagen 1alpha1 (Santa Cruz, sc-8784-R, 1:500), collagen 3alpha1 (Santa 
Cruz, sc-8781, 1:500), laminin gamma-1 (Santa Cruz, sc-5584, 1:5000), fibronectin 
(Santa Cruz, sc-9068, 1:500), α-tubulin (Calbiochem, CP06, 1:3000), GAPDH 
(Millipore, MAB374, 1:10,000), and β-actin (Santa Cruz, sc-47778, 1:2000). For studies 
involving siSMAD3, 1x105 hPSCs/well (6-well plate) growing in culture were 
transfected with 50 nM non-targeting siRNA control (Life Technologies, D-001810-01-
05) or siSMAD3 (Life Technologies, L-020067-00-005) using DharmaFECT®1 to inhibit 
endogenous SMAD3 levels in PSCs. 24 hours post-transfection, total proteins were 
harvested and subjected to western blot analysis to verify SMAD3 knockdown efficiency. 
For miR-29 expression analysis in TGF-β1-activated hPSCs transfected with siCTRL and 
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siSMAD3, hPSCs were transfected with 50 nM siCTRL or siSMAD3 as described. 24 
hours post-transfection, cells were serum starved for 24 hours, challenged with 10 ng/ml 
TGF-β1 for 24 hours, and subjected to Trizol RNA isolation.  miR-29 expression levels 
were analyzed via qPCR as described above. 
Co-culture 
1x105 mPSCs were transfected with either 20 nM mimic control, 20 nM mimic-
29a, or 20 nM mimic-29b and plated simultaneously with 100 pancreatic cancer cells 
(MIA PaCa2 or Panc-1) in a 6 well plate. Co-cultures were allowed to grow for 10 days, 
and were fixed and stained with crystal violet solution (0.05% w/v crystal violet, 1% 
formaldehyde, 1x PBS, 1% MeOH) or Sirius Red. Cancer colonies greater than 50 cells 
were counted under phase contrast microscopy. 
Collection of PSC Conditioned Media. To obtain miR-29 and control mimic transfected 
PSC conditioned media, exponentially growing mPSCs were seeded in a 6 well plates at 
1x105 cells per well, serum starved for 24 hours, and treated with 10 ng/ml of TGF-β1 for 
24hrs before transfection with 20 nM control or miR-29 mimics using  
DharmaFECT®1 per their protocol. 24 hours post-transfection, cells were washed 
twice with PBS and incubated with DMEM with 0.2% BSA for 48 hours at 
37oC. Conditioned media was collected from PSCs and centrifuged at 1500 rpm for 
10min at 4oC. Supernatant was collected and then filtered using a 0.22 µm sterile filter 
(Fisher Scientific, 09-719A) to eliminate any remaining suspended cells or cellular debris. 
In parallel, non-conditioned media control was collected from a 6 well plates with no 
PSCs. 
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Cell Viability 
1.0x103 PSCs were plated per well in a 96 well plate. Cells were serum starved 
for 24 hours, and treated with 10 ng/ml of TGF-β1 for 24 hours before transfection with 
20 nM control or miR-29 mimics using DharmaFECT®1 per their protocol. Cell viability 
was measured at 24, 48, 72, and 96 hours after plating the assays by adding 10 µl Cell 
Counting Kit-8 (Dojindo #CK04) reagent and absorbance was measured at 450 nm.  For 
cancer cells viability,  
5.0x103 pancreatic cancer cells (MIA PaCa-2 or Panc-1) were plated per well in a 
96-well plate. Cancer cells were washed with PBS, and treated with PSC conditioned 
media for 24 and 48 hours. Cell viability was measured post-treatment by adding 10 µl of 
Cell Counting Kit-8 reagent and absorbance was measured at 450 nm. 
Soft agar assays 
24 hours post-transfection with 20 nM control or miR-29 mimics, 5.0x104 mPSCs 
were co-seeded with 5.0x103 pancreatic cancer cells (MIA PaCa-2 or Panc-1) per well in 
a  6 well plate containing 0.5% top agarose and 1% bottom agarose (BioRad, #162-
0137). After 7 days, colonies were stained with crystal violet and were counted under low 
power for positive colonies (>6 cells/colony). 
Histology  
 FFPE pancreata of KC and C57BL/6 mice or normal control and PDAC patients 
were sectioned (5 µm) and stained with H&E for gross histological analysis. Tissue 
sections were also stained with Sirius Red to estimate collagen and the degree of fibrosis. 
ImageJ analysis was used to quantify Sirius Red positive collagen area in the pancreatic 
sections (four 20X random images/animal).   
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Immunofluorescence 
 1.0x105 mouse PSCs, human PSCs or primary human fibroblasts were plated on 
collagen coated cover slips in 6-well plates and grown to ~80% confluency. Cells were 
washed with PBS, fixed in 4% paraformaldehyde at 37°C and then permeabilized with 
0.25% Tween-20 in PBS (PBS-T). Subsequently, cells were blocked with 1% BSA in 
PBS-T at room temperature and α-SMA primary antibody (α-SMA, Novus Biologicals, 
NB600-531, 1:500) and secondary antibody (Goat-α-Rabbit-594, Molecular Probes, 
11012, 1:500) were used to detect intracellular α-SMA levels. Slides were coversliped 
using VectaShield mounting medium with DAPI (H-1200). 
In Situ Hybridization 
FFPE pancreata of C57BL/6 control mice at 2 and 10 months (n=3/group) and KC 
mice at 1, 4, and 9 months (n=3/group) were sectioned and subjected to in situ 
hybridization as previously described(115). FFPE pancreatic tissue sections (5 µm) from 
normal control and PDAC patients (n=4/group) were also subjected to miR-29 in situ 
hybridization as described. Slides were hybridized with 50 nM 5’-biotin labeled U6 
snRNA LNA probe (Exiqon, 99002-03) and 5’ and 3’ DIG labeled miR-29a LNA probe 
(Exiqon, 10000-899999-15) for 90 minutes at 55oC. Subsequently, slides were probed 
with antibody against GFAP (Novus Biologic, NB300-141, 1:200) or CK19 (Abcam, 
ab52625, 1:200) and stained with secondary antibodies conjugated to HRP to facilitate 
Tyramide signal amplification (TSA) reaction: goat anti-rabbit IgG (Santa Cruz, sc-2004, 
1:500-1:1000), anti-Dioxigenin (Abcam, ab6212, 1:200), and Streptavadin (Thermo 
Scientific, #21130, 1:5000). Slides were then stained with Hoechst NucRedTM Dead 647 
(Life Technologies) to stain nuclei. 20X images were taken using DeltaVision Core 
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confocal microscope, projected in four channels, pseudo-colored, and merged. Corrected 
total cell fluorescence (CTCF) of miR-29a (green) was quantified in six or more 
randomly selected GFAP-positive PSCs/fibroblasts or CK19-positive epithelial cells 
using ImageJ analysis as previously described (116).  
Statistical analysis  
Student’s t-test was used for statistical analysis. Data is presented as mean and 
error bars are represented as standard error of the mean. Statistical significance denoted 
as # p< 0.08, *p< 0.05, **p< 0.01. All experiments were repeated 3 or more times in 
biological replicates.   
 
2.3 Results  
TGF-β1 activates PSCs, downregulates miR-29, and increases ECM protein expression. 
In PDAC, activated PSCs are the major stromal cells responsible for fibrotic stroma. In 
an effort to evaluate the role of miR-29, an anti-fibrotic miRNA, in PSC-mediated 
stromal deposition, we challenged immortalized mouse PSCs and primary human PSCs 
with TGF-β1, a proinflammatory growth factor that is associated with PDAC 
pathogenesis (102) and that is known to activate quiescent PSCs (104). Subsequently, we 
examined miR-29 family (-29a, -29b & -29c) expression in TGF-β1 activated mouse and 
human PSCs by qPCR analysis. Both mouse and human PSCs stimulated with TGF-β1 
showed a significant loss of miR-29a and miR-29b compared to nascent cells, with no 
significant difference in miR-29c (Figure 4A, Figure 5). TGF-β1 bound TGF-β receptors 
form an activated heterotetramer (type I and type II) with serine/threonine kinase activity 
which phosphorylates downstream transcription factors, Smad2 and Smad3 proteins 
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(117).  Upon phosphorylation and activation, pSMAD2/3 form a heterogeneous complex 
with SMAD4, translocates into the nucleus, and directly regulates target gene expression. 
To verify the activation of TGF-β1 signaling in PSCs, we examined the levels of its 
downstream effector molecules, pSMAD2/3.  PSCs treated with TGF-β1 showed a 
significant increase in pSMAD2/3 levels with no difference in total SMAD2/3 expression 
in both mouse and human PSCs (Figure 4B, Figure 6). To further confirm TGF-β1-
mediated activation of PSCs and TGF-β1 signaling, we evaluated the expression of α-
SMA, a myofibroblast/PSC activation marker (104), and connective tissue growth factor 
(CTGF), a transcriptional target and mediator for the pro-fibrotic effects of TGF-β1. We 
observed a decrease in miR-29a and miR-29b expression (Figure 4A) with a concurrent 
increase in α-SMA (Figure 4C) and CTGF (Figure 4D) expression. Upregulation of TGF-
β1 and CTGF has been well documented in human PDAC and chronic pancreatitis, a 
major risk factor for PDAC (102, 103, 118), and causes an increase in the accumulation 
of stromal ECM proteins: collagen, laminin, and fibronectin (12). Furthermore, collagen 
and laminin are direct targets of miR-29 (92), and fibronectin is an indirect target of miR-
29 (94). We observed their significant increase in PSCs treated with TGF-β1 in 
conjunction with a loss of miR-29a and miR-29b (Figure 4E, Figure 7). Consistently, 
overexpression of miR-29 has been shown to suppress the fibrosis of various organs, 
including heart (92), liver (93), lung (94), kidney (95), and muscle (96) by reducing ECM 
deposition.  
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Figure 4. TGF-β1-mediated activation of PSCs leads to downregulation of miR-29 
and increases ECM protein expression. Mouse PSCs (mPSCs) and human PSCs 
(hPSCs) were serum starved for 24hours and stimulated with 10 ng/ml of TGF-β1 for 
24hours. Total RNA or protein were isolated for qPCR and western blot analysis 
respectively. (A) qPCR measurements of levels of miR-29 family members in nascent 
and TGF-β1 stimulated mPSCs and hPSCs. (B) Activation of pSMAD2/3 in TGF-β1 
stimulated mPSCs. Serum starved mPSCs were treated with TGF-β1 for 6hours and 
protein lysates were prepared and subjected to western blot analysis using antibodies 
against pSMAD2/3 and total SMAD2/3, as indicated. β-actin and GAPDH were used as 
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loading controls. (C) Measurements of mRNA by qPCR and immunofluorescence 
analysis of PSC activation marker, alpha smooth muscle actin (α-SMA) in TGF-β1 
stimulated mPSCs. Representative images are shown, α-SMA (red) and nuclear stain, 
DAPI (blue). (D) Meaures of TGF-β1 responsive gene target, connective tissue growth 
factor (CTGF) mRNA, in nascent and TGF-β1 stimulated mPSCs. (E) Western blot 
analysis of extracellular matrix proteins: collagen 1alpha1 (collagen 1a1), collagen 
3alpha1 (collagen 3a1), laminin gamma-1 (laminin), and fibronectin in nascent and TGF-
β1 activated mPSCs. α-tubulin, or GAPDH, or β-actin were used as loading controls. 
Relative quantification of band intensities, normalized to loading controls, are shown 
below respective blots. Experiments were repeated 3-4 times and representative data are 
shown. Data is presented as the mean + standard error of the mean (SEM); n= 3; p-values 
determined by t-test, *p< 0.05, **p< 0.01. 
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Figure 5. miR-29 expression analysis in an additional mouse PSC cell line. An 
additional immortalized mouse pancreatic stellate cell line (imPSC3) was serum starved, 
activated with 10 ng/ml TGF-β1 for 24 hours, and subjected to RNA extraction. miR-29a, 
miR29b, and miR-29c expression levels were analyzed by qPCR using U6 snRNA as an 
internal control. Data is presented as mean + SEM; n=3, statistics generated by t-test, 
*p<0.05. 
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Figure 6. TGF-β1 mediated activation of human PSCs leads to an increase in 
pSMAD2/3 expression levels. hPSCs were serum starved for 24 hours and treated with 
10 ng/ml TGF-β1 for 1 hour. Total proteins were harvested and subjected to western blot 
analysis of phosphorylated SMAD2/3 (pSMAD2, pSMAD3) and total SMAD2/3. 
GAPDH was used as a loading control. 
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Figure 7. TGF-β1 activated PSCs exhibit increased expression of ECM components 
at the mRNA and protein level. (A) mPSCs were serum starved for 24 hours and then 
stimulated with 10 ng/ml TGF-β1 for 24 hours. Total RNA was extracted and used to 
quantify miR-29 targets, and collagen 1a1 (COL1A1), laminin (LAMC1), and fibronectin 
(FN1) mRNAs. Data is presented as mean + SEM; n=6/group, statistics generated by t-
test, *p<0.05. (B) Western blot analysis of ECM protein levels of collagen 1a1, collagen 
3a1, laminin gamma-1 (laminin) and fibronectin in hPSCs, which were serum starved and 
treated with TGF-β1 for 24 hours. GAPDH was used as loading control. Relative 
quantification of band intensities, normalized to loading controls, are shown below 
respective blots. 
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TGF-β1 downregulates miR-29 in human fibroblasts and cancer associated fibroblasts.  
In addition to PSCs, pancreatic fibroblasts are also known to play a role in the stromal 
reaction associated with PDAC tumors (96, 99). To understand whether the loss of miR-
29 is common in TGF-β1 activation, we treated normal primary human pancreatic 
fibroblasts with TGF-β1 and quantified miR-29 expression levels. Similar to PSCs, TGF-
β1-activated primary fibroblasts had decreased miR-29a expression compared to nascent 
cells (Figure 8A), suggesting that the loss of miR-29a is consistent in both activated PSCs 
and fibroblasts. During PDAC initiation and progression, normal pancreatic fibroblasts 
convert into an activated state and are known as cancer associated fibroblasts (CAFs).  In 
addition to PSCs, CAFs have been shown to play a role in PDAC stromal deposition (99), 
initiation (119), progression, and metastasis (120). To determine whether TGF-β1 
dependent loss of miR-29 is a common phenomenon in CAFs, we examined the effects of 
TGF-β1 treatment on miR-29 expression in primary CAFs isolated from PDAC patients. 
Similarly, CAFs challenged with TGF-β1 showed a significant decrease in the expression 
of miR-29 family members (Figure 8B), suggesting that the loss of miR-29 function is a 
common phenomenon of activated stromal cells associated with fibrotic stromal 
deposition.  
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Figure 8. TGF-β1 downregulates miR-29 in human fibroblasts and cancer 
associated fibroblasts. Primary human pancreatic fibroblasts or cancer associated 
fibroblasts (CAFs) isolated from human PDAC tumors were stimulated with 10 ng/ml of 
TGF-β1 for 24 hours, and total RNA was isolated for miR-29 expression analysis. (A) 
qPCR analysis of miR-29 family members in TGF-β1 activated primary human 
pancreatic fibroblasts or (B) PDAC CAFs (n= 3). Data is presented as the mean + SEM; 
n= 3; p-values determined by t-test, *p< 0.05, # p< 0.08, **p< 0.01. Experiments were 
repeated three times and representative data are shown. 
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Activation of KrasG12D in the pancreas leads to loss of miR-29 and increased collagen 
deposition. Activating mutations in the proto-oncogene KRAS are common in 90%–95% 
of PDAC patients, and KrasG12D is the most frequently found genetic aberration (121).  In 
order to explore the effects of KrasG12D on miR-29 expression, we collected pancreata 
from a well-characterized PDAC mouse model, KC(113), at 1-9 months of age and 
examined global pancreatic miR-29 expression and collagen/connective tissue deposition. 
We observed a significant loss of miR-29 expression in KC mice compared to C57BL/6 
controls (Figure 9A) in conjunction with a significant increase in pancreatic 
fibrosis/collagen estimation by gross histopathological examination (H&E and Sirius Red 
stain) (Figure 9B) and quantification of Sirius Red positive collagen (Figure 9C).  
 
Global loss of miR-29 expression in human PDAC tumors. To determine the miR-29 
expression patterns in human PDAC tumors and establish its clinical relevance, we 
examined miR-29 expression in PDAC patient biopsies with 35-80% tumor stroma, 
assessed by Sirius Red staining, and compared them to normal patient control samples.  
Similar to KC mice, we observed a significant decrease in all miR-29 family members in 
PDAC tumor samples compared to normal patient controls (Figure 9D). Furthermore we 
conducted H&E and Sirius Red staining and observed a corresponding increase in 
fibrosis in PDAC tumor biopsies by both gross histopathological examination (Figure 
10A) and quantification of Sirius Red staining (Figure 10B). Corresponding patient 
clinical data of each sample is provided in Table 1 and Table 2. 
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Figure 9. Global loss of miR-29 is a common phenomenon of KrasG12D-activated 
murine pancreata and human PDAC tumors with increased collagen deposition. (A) 
miR-29 expression levels in KC, PDAC mouse model. Total RNA was isolated from 
formalin fixed paraffin embedded (FFPE) pancreatic tissue sections of KC or C57BL/6 
control mice (n= 3–5 animals/time point) and subjected to miR-29 expression analysis 
via qPCR. (B) Representative H&E and Sirius Red stained pancreatic sections from 
C57BL/6 control and KC mice (9 months). Acinar cells “A”, Islets of Langerhans “IL”, 
pancreatic ducts “D”, and prominent fibrosis “F” are demonstrated in the KC animals. 
(C) Quantification of collagen in KC animals from 1–9 months of age. ImageJ was used 
to quantify Sirius Red positive collagen. Data is presented as the mean± SEM; n= 3 to 5 
animals/time point; (D) miR-29 expression analysis in PDAC patient tumors. Total RNA 
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was isolated from FFPE sections of normal controls (n= 10) (N; solid black) or PDAC 
patient tumors (n= 15) with 35–80% stroma (T; red, green, or blue), and miR-29 
expression was analyzed by qPCR. miR-29 family members are represented by circles 
(miR-29a), squares (miR-29b), and diamonds (miR-29c). For each group, the mean 
expression of miR-29 family members is indicated as horizontal lines. p-values 
determined by t-test, *p< 0.05. 
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Figure 10. Pancreatic tissues from PDAC patient samples display a high degree of 
fibrosis. (A) Representative H&E and Sirius Red stained pancreatic sections from normal 
controls or PDAC patient tumors. Acinar cells “A”, Islets of Langerhans “IL”, pancreatic 
ducts “D”, and prominent fibrosis “F” are demonstrated in the PDAC patients. (B) 
Quantification of fibrosis/collagen in normal and PDAC patients. FFPE sections from 
normal and PDAC patient tumors were stained with H&E for gross histological analysis 
and Sirius Red to estimate the degree of fibrosis/collagen. Percent fibrosis in normal 
patient controls (n=10) and PDAC patient tumors (n=15) was calculated using Sirius Red 
positive pancreatic sections (four 20X random images/patient). ImageJ was used to 
quantify Sirius Red positive area. The mean percentage of fibrosis/collagen for each 
group is shown as horizontal lines. Statistics were generated using t-test, **p<0.01. 
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Table 1: Clinical PDAC Patient Data 
 
 
Source: Indiana University Simon Cancer Center Tissue Bank and Department of 
Pathology 
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Table 2 Clinical Sample ID and Information 
 
Source: Indiana University Simon Cancer Center Tissue Bank and Department of Pathology.  
 
Table Description: “Sample type” indicates normal pancreas versus PDAC tumor biopsies. “Source” indicates the source of biopsies, 
either IU Pathology department (IU Pathology) or IU Simon Cancer Center (IUSCC). “Sample ID” indicates arbitrary sample name 
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for purposes of internal documentation. “% of stroma” indicates % area of Sirius Red positive staining as assessed by histology for 
respective samples. “Age”, “Sex”, “Ethnicity” are descriptors of patients at time of biopsy. “Tumor location in pancreas – Head/Tail” 
indicates the location in which the biopsy was taken from the patient pancreas. “Stage” indicates the grade of primary tumor (T), 
lymph node spread (N), and degree of metastasis (M). “Lymph Node-Positive/Negative” indicates the presence of metastatic events 
within the lymph node. “Lymphovascular invasion (LVI) – positive/negative” indicates presence or absence of metastatic events 
within patient vasculature. “Perineural invasion (PNI) – positive/negative” indicates spread of cancer near or surrounding a nerve. 
“pTumor size” indicates the degree of tumor growth. “Tumor Grade” indicates the degree of differentiation of cancer cells. “Margins” 
indicate whether the sampled biopsy encompasses the entirety of the tumor (negative) as indicated by the presence of normal tissue 
surrounding the tumor or only encompasses only a portion of the tumor (positive).   
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PSC and epithelial cell specific miR-29 loss of expression in KC mice and human PDAC 
tumors. As we observed global loss of miR-29 in both human PDAC tumors and KC mice, 
to examine PSC and epithelial cell specific miR-29 expression patterns in PDAC tumors 
and KC mice pancreata, we performed in situ hybridization of miR-29a, the most 
abundantly expressed miR-29 family member in PSCs, epithelial cells, and the pancreas 
(Figure 11). To assess PSC specific miR-29 expression, we co-stained PDAC tumors and  
KC mice pancreata with miR-29a and glial fibrillary acidic protein (GFAP), a cell marker 
of both active and inactive PSCs/fibroblasts(122). Consistent with PSCs/fibroblasts 
challenged with TGF-β1, GFAP- positive cells of PDAC tumors displayed a significant loss 
of miR-29a compared to normal patient control pancreata (Figure 12).  Similarly, KC mice 
displayed significant loss of miR-29a in GFAP-positive cells compared to control mice at 
early (2-4 months) and late ages (9-10 months) (Figure 13).  
To examine epithelial cell specific miR-29 expression patterns, we co-stained 
human PDAC tumors and KC mice pancreata with miR-29a, and Cytokeratin-19 (CK19), a 
cell marker specific to epithelial cells (123) . Similar to PSCs, CK19 positive epithelial 
cells of PDAC tumors (Figure 12C, Figure 12D) and KC mice (Figure 14) showed a 
significant loss of miR-29 expression compared to normal controls, indicating that the 
global loss of miR-29 may be attributed by both stromal PSCs and epithelial cells. 
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Figure 11. miR-29a is the most abundantly expressed miR-29 family member in 
pancreatic stellate cells, pancreatic ductal epithelial cells, and the whole pancreas. 
miR-29a, -29b, -29c expression was measured in RNA isolated from (A) nascent hPSCs 
(serum starved 24hrs), (B) pancreatic ductal epithelial cells (HPDE) (n=3), or (C) normal 
human pancreas (n=5), by qPCR using U6 snRNA as an internal control. Delta CT (∆CT) 
was calculated for each miR-29 family member to measure relative expression levels. 
Boxplots represent -1/ ∆CT of miR29 expression levels in (hPSC, HPDE, or normal 
human pancreas,). Statistics calculated using student t-test, *p<0.05. 
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Figure 12. PSC and epithelial cell specific miR-29 loss of expression in human 
PDAC tumors. (A, C) In situ hybridization of miR-29 in PSCs (A) and epithelial cells 
(C) of normal control and PDAC patient tumors. FFPE pancreatic tissue sections from 
normal control and PDAC patients (n = 4/group) were subjected to miR-29a in situ 
hybridization. Representative images are presented as a single channel or merged (scale 
bar is 5 µm, 20X magnification). Hoechst nuclear stain (magenta), U6 (red), miR-29a 
(green), and GFAPpositive PSCs or CK19-positive epithelial cells (blue). (B, D) 
Corrected total cell fluorescence (CTCF) of miR29a in PDAC tumors (n = 4) compared 
to control patients (n = 4) was calculated for each patient averaging six or more randomly 
selected GFAP-positive PSCs (B) or CK19-positive epithelial cells (D) using ImageJ 
analysis. Data represents mean + SEM. Statistics were generated using t-test, *p < 0.05. 
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Figure 13. miR-29a is decreased in GFAP-positive PSCs in KC mice. In situ 
hybridization of miR-29a in pancreata of control mice (C57BL/6) and KC mice at early 
and late time points. FFPE pancreatic tissue sections collected at (A) early (2-4 months) 
and (B) late (9-10 months) time points from C57BL/6 control or KC mice 
(n=3/group/time point) were subjected to miR-29a in situ hybridization and images were 
generated using tyramide substrate amplification technique. Corrected total cell 
fluorescence (CTCF) of miR-29a was calculated for each animal by averaging six 
randomly selected GFAP-positive PSCs/fibroblasts using ImageJ analysis. Data 
represents the mean + SEM; n=3; statistics generated by t-test, *p<0.05. Representative 
images are presented as a single channel, or merged (scale bar is 5 µm, 20X 
magnification). Hoechst Nuclear stain (magenta), U6 (red), miR-29a (green), and GFAP 
(blue). 
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Figure 14. miR-29a is decreased in CK19-positive epithelial cells in KC mice. In situ 
hybridization of miR-29a in pancreata of control mice (C57BL/6) and KC mice. FFPE 
pancreatic tissue sections collected from 9-10 month old C57BL/6 control or KC mice 
(n=3/group/time point) were subjected to miR-29a in situ hybridization and images were 
generated using tyramide substrate amplification technique. Corrected total cell 
fluorescence (CTCF) of miR-29a was calculated for each animal by averaging six or 
more randomly selected CK19-positive epithelial cells using ImageJ analysis. Data 
represents the mean + SEM; n=3; statistics generated by t-test, *p<0.05. Representative 
images are presented as a single channel, or merged (scale bar is 5 µm, 20X 
magnification). Hoechst Nuclear stain (magenta), U6 (red), miR-29a (green), and CK-19 
Epithelial stain (blue). 
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Physiological role of miR-29 in PSC-mediated stromal ECM protein accumulation. Since 
the loss of miR-29a/b was commonly observed in PSCs/fibroblasts challenged with TGF-
β1, in KrasG12D expressing murine pancreata, and in human PDAC biopsies, we performed 
in vitro gain/loss-of-function studies to determine the physiological role of miR-29 in PSC-
mediated stromal protein expression using synthetic miR-29 mimics and miR-29 locked 
nucleic acids (LNAs), a miR-29 family inhibitor. To test the effect of miR-29 gain-of-
function on PSC-mediated stromal accumulation, we transfected mouse and human PSCs 
with control, miR-29a, or b mimics, after TGF-β1 treatment, and examined ECM protein 
levels. We confirmed the increase of exogenous miR-29a and miR-29b in both mouse and 
human PSCs transfected with synthetic miR-29a/b mimics (Figure 15). As expected, we 
observed a significantly lower expression of direct miR-29 ECM protein targets (Figure 
16A) in PSCs transfected with miR-29 mimics compared to cells transfected with control 
mimic (Figure 16B, Figure 17). Interestingly, in miR-29 overexpressed PSCs, we also saw 
a decrease in fibronectin, a major ECM protein in PDAC stroma and a known indirect 
target of miR-29 (94) (Figure 16B, Figure 17).   
In order to better understand the underlying mechanism for miR-29-mediated 
fibronectin repression in TGF-β1 activated PSCs, we investigated the effect of miR-29 on 
TGF-β1 signaling. We observed a decrease in pSMAD2 levels in PSCs transfected with 
miR-29a or miR-29b compared to control mimic (Figure 16C, Figure 18), suggesting an 
indirect effect of miR-29 on fibronectin suppression. 
For miR-29 loss-of-function studies, we transfected TGF-β1 activated PSCs with 
control or miR-29 LNAs and assessed the effects on stromal protein accumulation. We 
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confirmed the knockdown of all three miR-29 family members in PSCs transfected with 
miR-29 LNAs (Figure 19). Inhibition of miR-29 by LNAs led to a further increase in 
accumulation of ECM proteins (Figure 16D and Figure 20).  
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Figure 15. Mouse and human PSCs transfected with miR-29 mimics have increased 
exogenous miR-29a and miR-29b. (A) mPSCs and (B) hPSCs were transfected with 25 
nM control, miR-29a, or miR-29b mimics. 24 hours post-transfection, RNA was 
extracted and miR29a and miR-29b expression levels were quantified by qPCR using U6 
snRNA as an internal control. Data is presented as mean ∆CT values + SEM; n=3, 
statistics calculated using student t-test, **p<0.01. 
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Figure 16. Physiological role of miR-29 in PSC-mediated stromal ECM protein 
accumulation. For miR29 gain and loss-of-function studies, serum starved and TGF-β1 
(10 ng/ml, 24hours) treated PSCs were transfected with synthetic miR-29 mimics or miR-
29 locked nucleic acids (LNAs), a miR-29 family inhibitor respectively. Subsequently, 
the effects of miR-29 gain and loss-of-function on extracellular matrix (EMC) proteins 
was evaluated by western blot analysis. (A) Schematic representation of the miR-29 
family members, and 3′-UTR binding sites of miR-29 ECM targets. miR-29 encoding 
loci are located on human chromosome 7 (miR-29a/miR-29b-1) and chromosome 1 
(miR-29b-2/miR-29c). All three miR29 family members (miR-29a, miR-29b, and miR-
29c) have identical seed sequences. miR-29 binding sites in the 3′-UTR of ECM protein 
transcripts encoding collagen 1a1 (COL1A1), collagen 3a1 (COL3A1), and laminin 
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gamma-1 (LAMC1) are depicted. (B) Western blot analysis of ECM proteins in miR-29 
gain-of-function studies of hPSCs. TGF-β1 stimulated hPSCs were transfected with 20 
nM mimic control (ctrl), mimic-29a (29a), or mimic-29b (29b). 24hours post-
transfection, total proteins were harvested and subjected to western blot analysis of ECM 
proteins (collagen 1a1, collagen 3a1, laminin, and fibronectin). (C) Western blot analysis 
of pSMAD2 in miR-29 overexpressed hPSCs. Serum starved and TGF-β1 treated hPSCs 
were transfected with miR-29 (20 nM) or control mimics (20 nM). 24 hours post-
transfection, protein was harvested and subjected to western blot analysis for pSMAD2 
and SMAD2. (D) Western blot of collagen 1a1, collagen 3a1, and laminin in hPSCs 
transfected with LNA-ctrl or miR-29 family inhibitor (LNA-29). TGF-β1 treated hPSCs 
were transfected with 50 nM of LNA-29 or LNA-control. 24hours post-transfection, 
protein was harvested and subjected to western blot analysis. Relative quantification of 
protein band intensities, normalized to GAPDH loading control, are shown below each 
blot. Each experiment was repeated three times and representative data are presented. 
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Figure 17. Ectopic expression of miR-29 mimics reduce ECM components in TGF-
β1 activated mouse PSCs. Mouse PSCs were serum starved for 24 hours and activated 
with 10 ng/ml TGF-β1. 48 hours post-treatment, PSCs were transfected with miR-mimics 
(29a, 29b, or control) for 24 hours, and total proteins isolated. Western blot analysis was 
performed to determine the expression levels of ECM proteins (collagen 1a1, collagen 
3a1, laminin gamma-1, and fibronectin) using GAPDH as a loading control. Relative 
quantification of protein band intensities, normalized to loading controls are shown below 
respective blots. 
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Figure 18. miR-29 suppresses SMAD2 activation in mouse PSCs. mPSCs were 
transfected with 25 nM miR-mimics, miR-29a (29a), miR-29b (29b), or mimic control 
(ctrl). Cells were then serum starved for 24 hours and activated with 10 ng/ml TGF-β1 for 
24 hours. Western blot analysis of pSMAD2 and SMAD2 was performed. Relative 
quantity was measured using GAPDH as a loading control and are shown below 
respective blots. 
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Figure 19. LNA-miR-29 efficiently knockdown all endogenous miR-29 family 
members (miR-29a, miR-29b, and miR-29c) in mouse and human PSCs. (A) mPSCs 
and (B) hPSCs were transfected with 25 nM LNA-control or LNA-miR-29 (LNA-29). 24 
hours posttransfection, total RNA was isolated and miR-29 expression was quantified 
using qPCR analysis. Data is presented as mean + SEM; n=3, statistics generated by 
student’s t-test, **p<0.01. 
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Figure 20. miR-29 knockdown increases direct miR-29 ECM target proteins in 
mouse PSCs. mPSCs were starved for 24 hours, activated with 10 ng/ml TGF-β1 for 24 
hours, and transfected with LNA-control (ctrl) or LNA-29 (29). 24 hours post-
transfection, total proteins were harvested to examine ECM proteins, collagen 1a1, 
collagen 3a1, and laminin gamma-1 (laminin) by western blot analysis. Measurements of 
GAPDH were used as a loading control. Relative quantification of band intensities 
normalized to loading control and are shown below respective blots. 
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Ectopic expression of miR-29 in PSCs reduces stromal deposition, cancer cell viability, and 
colony growth in co-culture. Subsequently, to evaluate the effects of miR-29 
overexpression in PSCs on cancer growth, we transfected PSCs with control or miR-29 
mimics and co-cultured them with pancreatic cancer cells. Direct co-culture of PSCs 
overexpressing miR-29a or b with pancreatic cancer cells caused a significant decrease in 
the ability of the cancer cells to form colonies (Figure 21A, Figure 22A) and reduced 
stromal deposition associated with cancer colonies (Figure 22B). To elucidate the 
underlying mechanism that leads to a decrease in pancreatic cancer colony formation, we 
evaluated the autocrine and paracrine effects of miR-29 on the viability of PSCs and 
pancreatic cancer cells, respectively. For autocrine effects of miR-29, we transfected PSCs 
with control or miR-29 mimics, and cell viability was monitored for up to 96 hours post-
transfection. Overexpression of miR-29 did not reduce PSC viability compared to cells 
transfected with control mimics (Figure 23). To determine the paracrine effects of miR-29 
on cancer cell viability, pancreatic cancer cells were cultured in conditioned media 
collected from PSCs transfected with control or miR-29 mimics. We observed a significant 
decrease in viability of pancreatic cancer cells growing in conditioned media collected from 
miR-29 transfected PSCs compared to PSCs transfected with control mimics (Figure 21B). 
Finally, to evaluate the effect of miR-29 overexpression in PSCs on anchorage independent 
growth of pancreatic cancer cells, we co-cultured miR-29 transfected PSCs with cancer 
cells in soft agar assays. We observed a decrease in anchorage independent growth of 
pancreatic cancer cells when co-seeded with miR-29a overexpressing PSCs compared to 
PSCs transfected with control mimics (Figure 24). Overall, overexpression of miR-29 in 
PSCs caused a decrease in stromal/ECM protein accumulation and cancer colony growth. 
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However, the long-term consequences of miR-29 overexpression in stromal deposition and 
cancer progression need to be further evaluated in vivo. 
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Figure 21. Ectopic expression of miR-29 in PSCs reduces cancer cells viability and 
cancer colony growth in co-culture. (A) Effect of miR-29 overexpression in PSCs on 
cancer colony growth in direct cocultures. mPSCs were transfected with 20 nM of mimic 
control, mimic-29a, or 29b. 24 hours post-transfection, mPSCs were plated 
simultaneously with 100 pancreatic cancer cells (Panc-1) in a 6-well plate. Co-cultures 
were allowed to grow for 10 days, fixed, and stained with crystal violet fixing solution to 
stain cancer cells as previously described (124) with few modifications. Cancer colonies 
greater than 50 cells were counted under phase contrast microscopy. Representative 
images of co-cultures stained with crystal violet are shown. (B) Conditioned media of 
PSCs expressing miR-29 show decreased effect on pancreatic cell viability. Conditioned 
media from mPSCs transfected with control, miR-29a, or miR-29b mimics was applied to 
pancreatic cancer cells (Panc-1) in a 96-well plate and viability was measured 24 and 
48hours post-treatment using the Cell Counting Kit-8 assay according to manufacture 
protocol. Data is normalized to pancreatic cancer cells (Panc-1) treated with non-
conditioned media. All experiments were repeated 3-4 times and representative data is 
presented. Data represents mean + SEM. Statistics generated by t-test, *p< 0.05, **p< 
0.01. 
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Figure 22. Ectopic expression of miR-29 in PSCs causes reduced cancer colony 
formation and stromal deposition in direct co-cultures. (A) mPSCs transfected with 
mimic control, miR-29a, or miR-29b were co-seeded in 6-well plates with MIA PaCa2 
cancer cells and cultured at 37°C for 10 days. Cancer colonies were stained with crystal 
violet and counted. Data is presented as relative percentage of cancer colonies normalized 
to mimic control; mean + SEM; n=3, statistics generated by student’s t-test, *p<0.05. (B) 
Effect of miR-29 overexpression in PSCs on stromal accumulation in direct co-cultures. 
Mouse PSCs transfected with mimic control, miR-29a, or miR-29b, were co-seeded in 6-
well plates with MIA PaCa-2 cancer cell lines, cultured at 37° for 10 days, fixed, and 
subjected to Sirius Red staining. Representative images of co-cultures stained with Sirius 
Red are shown. All experiments were repeated 3-4 times and representative data is 
presented. 
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Figure 23. Ectopic miR-29 expression does not affect PSC viability. PSCs were plated 
into 96-well plates, serum starved 24 hours, treated with 10 ng/ml TGF-β1 for 24 hours, 
and then transfected with miR-control, miR-29a, or miR-29b. Cell viability was measured 
at 24, 48, 72, and 96 hours using the Cell Counting Kit-8 assay and absorbance was 
measured at 450 nm. Data is presented as average relative absorbance + SEM; n=4-8, 
statistics generated by student’s t-test, but were not significant. 
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Figure 24. miR-29 decreases the effect of PSCs on anchorage independent growth of 
pancreatic cancer cells. mPSC transfected with mimic control, miR-29a, or miR-29b 
were coseeded in soft agar assay in a 6-well plate with pancreatic cancer cells (MIA 
PaCa-2) and were cultured at 37°C for 7 days. 500 µl of medium was supplemented 
every other day. Following 7 days, cells were stained with crystal violet. Cell numbers 
was meaured microscopically and representative images are shown. Number of colonies 
per well is presented as mean + SEM; n=6, statistics generated by student’s t-test, 
*p<0.05. 
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TGF-β1-mediated downregulation of miR-29 in PSCs is SMAD3 dependent. We next 
sought to identify the underlying mechanism of TGF-β1 activated loss of miR-29 in PSCs. 
An earlier report identified SMAD3 binding elements near the miR-29a/b-1 locus on 
chromosome 7 upstream of the miR-29a/b1 transcription start site (125) (Figure 25A). We 
subsequently knocked down SMAD3 by siRNA, a major downstream effector molecule of 
TGF-β1, which is known to directly regulate miR-29 expression in myoblast and renal 
cells (126, 127) and confirmed the loss of SMAD3 protein in transfected PSCs by 
western blot analysis (Figure 25B). PSCs transfected with control siRNA displayed a 
significant downregulation of miR-29a and miR-29b upon TGF-β1stimulation (Figure 
25C).  Whereas in the absence of SMAD3, PSCs no longer showed a significant change 
in miR-29 (Figure 25C), suggesting that the ability of TGF-β1 to suppress miR-29 
expression is SMAD3 dependent. Our results, in conjunction with previous findings in 
muscle and kidney (95, 128) suggests that TGF-β1-mediated loss of miR-29 in PSCs may 
be due to the direct binding of SMAD3 to miR-29 promoter elements. 
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Figure 25. TGF-β1-mediated downregulation of miR-29 expression in PSCs is 
SMAD3 dependent. (A) Predicted SMAD3 binding sites upstream of miR-29a/b1 
promoter: there are two SMAD3 binding elements (S3BE) 5 kb and 49 kb upstream of 
the transcription start site of the miR-29a/b1 loci on chromosome 7. SMAD3 binds 
specifically to CAGA boxes: AG(C/A)CAGACA and regulates neighboring gene 
expression. (B) siSMAD3 efficiently reduces endogenous SMAD3 protein levels in 
hPSCs. hPSCs growing in culture were transfected with 50 nM non-targeting siRNA 
(siCTRL) or siSMAD3. 24hours post-transfection, total proteins were harvested and 
 65 
subjected to western blot analysis to determine SMAD3 expression levels. GAPDH was 
used as a loading control. (C) SMAD3 knockdown abrogates TGF-β1-mediated miR29 
repression. qPCR analysis of miR-29 levels in TGF-β1-activated hPSCs transfected with 
siCTRL and siSMAD3. hPSCs were transfected with 50 nM siCTRL or siSMAD3. 
24hours post-transfection, cells were challenged with 10 ng/ml TGF-β1 for 24 hours and 
subjected to qPCR for miR-29 expression levels. All experiments were repeated three 
times and representative data is presented. Data are presented as mean + SEM; n= 3, 
statistics generated by t-test, *p< 0.05. 
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2.4 Discussion 
Dense, fibrotic stroma is a histopathological hallmark of pancreatic cancer, and it 
precludes drug delivery to the tumor bed (21, 98). Activated PSCs are major contributors of 
fibrotic stromal reaction and are known to interact with cancer cells and promote PDAC tumor 
progression (26, 100). Quiescent PSCs normally located within the periacinar/ductal regions of 
the pancreas are activated in response to autocrine and paracrine pro-inflammatory 
cytokines/growth factors and secrete excessive amount of ECM proteins, a major component of 
PDAC stroma (104). TGF-β1 is a pro-tumorigenic/fibrotic growth factor secreted from cancer cells 
and injured acinar cells and is known to be a vital contributor of PSCs activation (28, 104). The 
upregulation of TGF-β1 in PDAC has been well documented and perpetuates the stromal reaction 
(12, 102).   
Although previous studies have shown that miR-29 is reduced in TGF-β1 signaling and 
promotes fibrosis of various organs (126, 127), the role of miR-29 in the context of PSCs and 
PDAC fibrotic stroma has yet to be elucidated. In our study, we show for the first time that TGF-
β1 acts as a negative regulator of miR-29 in PSCs, while simultaneously upregulating ECM 
proteins: collagens, laminin and fibronectin. Through qPCR analysis, we observed a predominant 
downregulation of miR-29a and miR-29b family members in both mouse and human PSCs upon 
TGF-β1-mediated activation. In muscle and kidney fibrosis, TGF-β1 is known to downregulate 
miR-29 expression in myoblasts (126) and renal cells (127) through SMAD3 binding elements 
located upstream of miR-29 promoter region and promote fibrosis. Similarly, we found that TGF-
β1-mediated miR-29 repression in PSCs is SMAD3 dependent.  In addition to PSCs, TGF-β1 
activated pancreatic fibroblasts (99) (additional stromal cell responsible for stromal reaction), also 
displayed a loss of miR-29.  Interestingly, we found the downregulation of all three miR-29 
family members in TGF-β1 stimulated CAFs isolated from PDAC patient tumors. miR-29 family 
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members encoding genes reside on two different human chromosomes with miR-29a/b1 loci on 
Chromosome 7 and the miR-29c/b2 loci on Chromosome 1 (Fig 5a) (125), lending to the 
possibility that TGF-β1 may elicit downstream effects to inhibit both miR-29 encoding loci in 
CAFs but not in PSCs and normal pancreatic fibroblasts.  Our findings implicate a differential 
effect of TGF-β1 in regulation of miR-29 expression in CAFs compared to PSCs/pancreatic 
fibroblasts that warrants further studies and may reveal differential regulatory mechanisms 
between miR-29 family members.   
Subsequent investigation of miR-29 expression patterns in the pancreata of 
spontaneous tumor forming PDAC mouse model KC (113) and in PDAC patient tumor 
biopsies revealed similar findings of miR-29 loss of expression. We found a global 
decrease in expression of all three miR-29 family members in KrasG12D murine pancreata 
and human PDAC in conjunction with an increase in pancreatic fibrosis and stromal 
deposition associated with PDAC tumors. Although we observed a global loss of miR-29, 
these findings did not implicate whether the loss of miR-29 is specific to PSCs and 
epithelial cells associated with murine and human PDAC. Thus, we performed in situ 
hybridization to assess PSC and epithelial cell specific miR-29a expression by co-staining 
KC pancreata and human PDAC tumors with GFAP, a marker specific to 
PSCs/fibroblasts(122) and CK19, a marker specific to epithelial cells(123).  Accordingly, 
we found a similar loss of miR-29a in PSCs of KC mice and PDAC patient samples.  These 
findings further confirm that the loss of miR-29 is consistent in PSCs associated with 
PDAC stromal reaction. Nevertheless, our results do not document the underlying 
mechanisms for the loss of miR-29 expression in K-RasG12D activated murine pancreata and 
human PDAC tumors, but our findings advocate for future functional studies in vivo to 
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examine miR-29 expression patterns in disease onset and progression in various etiologies 
associated with human PDAC.   
Stromal ECM proteins such as collagens and laminin are direct miR-29 targets. 
These proteins in addition with fibronectin, another stromal abundant protein, interact 
with cancer cells and enhance tumor progression of various malignancies (129, 130) 
including pancreatic cancer (131). Although miR-29 has been shown to suppress fibrosis 
of several different organs, including heart (117), liver (93), lung (94), kidney (95), and 
muscle (110) by negatively regulating ECM protein expression, the function of miR-29 in 
PSC-mediated ECM protein expression has yet to be validated. Using miR-29 gain and 
loss-of-functions studies, we found that miR-29 suppresses its direct ECM targets 
collagen1a1, collagen 3a1, and laminin in activated PSCs. Surprisingly, we also found that 
miR-29 inhibits fibronectin expression, even though fibronectin does not contain canonical 
miR-29 binding sites within its 3’-untranslated region (Targetscan, miRanda, and PicTar). 
As a result, we sought to find an indirect mechanism for miR-29 mediated fibronectin 
inhibition in TGF-β1 activated PSCs.  Interestingly, we found that ectopic expression of 
miR-29 in TGF-β1 activated PSCs reduced SMAD2 phosphorylation, implicating that 
miR-29 may act as an auto-inhibitory feedback regulator within TGF-β1 signaling.  TGF-
β1 is known to play a key role in PDAC pathogenesis, and its upregulation has been well 
documented in PDAC (102) and pancreatitis (103), a major risk factor of PDAC. As a 
consequence, TGF-β1 has emerged as an appealing therapeutic target, and numerous 
therapeutic strategies have been developed to inhibit TGF-β1 signaling via ligand inhibition 
and ligand/receptor interactions(132). Our findings reveal miR-29 to be a potential 
downstream inhibitor of TGF-β1 signaling. 
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In addition to the fibrotic stromal reaction, PSCs are known to interact with 
pancreatic cancer cells and promote tumor progression and metastasis. In our functional 
studies, restored expression of miR-29 in PSCs caused a decrease in cancer colony growth 
and stromal protein accumulation associated with co-cultures. Our data suggests that miR-
29 overexpression reduced cancer colony growth by inhibiting the paracrine effects of 
PSCs on cancer cells, as we observed a decrease in pancreatic cancer viability.  The precise 
mechanism associated with the paracrine effect of miR-29 overexpression in PSCs on 
cancer cell growth has yet to be elucidated, and future studies would further shed light on 
the role of miR-29 in tumor-stromal interactions. A large body of experimental evidence 
documents the role of extracellular matrix protein such as collagen and laminin in cancer 
cell proliferation and drug resistance (133-135). Although, we observed that the 
overexpression of miR-29 in PSCs reduced stromal accumulation associated with cancer 
colonies, additional studies are required to elucidate the direct mechanistic role of miR-29 
in ECM-mediated pancreatic cancer progression.  
As fibrotic stroma impairs the efficacy of chemotherapeutics and promotes PDAC 
progression, it is considered as an attractive therapeutic target in developing effective 
treatment strategies to target PDAC. Anti-stromal therapies to date have sought to deplete 
the reactive stroma. However, these approaches failed to improve patient survival and are 
often associated with toxicity. Furthermore, recent studies show that stroma impedes 
tumor growth, and its complete inhibition accelerated disease progression10,(35). 
However, inactivating PSCs by modulation of a key transcriptional regulator suppressed 
the reactive stroma, increased tumor response to chemotherapy, and enhanced survival 
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(37). These findings suggest that normalizing reactive stroma is a safe and efficacious 
treatment strategy, as opposed to completely ablating the reactive stroma.  
In our studies using in vitro and in vivo models and PDAC patient biopsies, we 
observed a loss of miR-29 in PSCs and fibroblasts, the critical stromal cells responsible for 
fibrotic stroma. Restored expression of miR-29 in PSCs suppressed major stromal protein 
expression (collagens, laminin and fibronectin) and inhibited cancer cell growth in co-
culture. While the long-term consequences of miR-29 overexpression or miR-29 loss-of-
function on PDAC progression/metastasis and its role in cancer cells and the tumor 
microenvironment remain to be investigated in vivo, our findings indicate that the efficacy 
of stroma-targeted therapy in PDAC may also be dictated by stromal miRNA expression 
and function. We anticipate that the restored expression of miR-29 in stromal cells reduces 
the stromal protein accumulation and cancer growth and enhances the drug delivery to the 
inner tumor core. Furthermore, increasing evidence indicate miR-29 plays a vital role in 
cancer pathogenesis (111), tumor microenvironment, and metastasis (112). In contrast to 
pharmacological approaches, the use of miR-29 as a therapeutic agent may be more 
effective in targeting reactive stroma, as a single miRNA regulates the expression of 
several genes associated with disease mechanisms (108). Thus, restored expression of a 
critical miRNA is therapeutically beneficial and targets multiple cellular pathways 
associated with disease processes. In our previous work, we demonstrated that the 
replacement of a single missing miRNA suppressed tumor progression with no toxicity 
and off-target effects (136). 
Thus far, no studies have interrogated the relevance of miR-29 in the context of 
PDAC stroma.  Based on our in vitro, in vivo, and clinical observations in stromal cells and 
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functional studies, our results indicate that miR-29 plays a critical role in stromal 
deposition and inhibits the pro-growth effects of PSCs on pancreatic cancer colony 
formation. Our findings raise the possibility that miR-29 could serve as an anti-stromal 
therapeutic agent in the context of PDAC. A large body of evidence demonstrates the 
pleiotropic role of miRNAs in fibrotic process, cancer pathogenesis and metastasis, and 
their potential use as therapeutic agents for cancer (136-138), fibrosis (139), and other 
human diseases (140). Some miRNA-based drugs have already reached clinical trials (140, 
141) or are in advanced stage of pre-clinical development(142, 143), indicating the 
feasibility of miR-29 in prospective clinical applications. This new and substantially 
different approach is expected to overcome the problems associated with other means of 
modulating the stroma and result in an effective approach to improve drug delivery to the 
tumor bed. Future work aimed at determining the role of miR-29 in pancreatic cancer cells, 
patient survival, and its biological functions in vivo will allow us to further understand the 
role of miR-29 in PDAC development and progression and ultimately determine its 
prognostic and therapeutic applicability to target PDAC.  
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Chapter 3: Novel role of miR-29a in pancreatic cancer autophagy and its 
therapeutic potential  
3.1 Introduction 
PDAC is one of the most lethal forms of human malignancies worldwide with 
poor prognoses (144). In the United States, PDAC is the fourth leading cause of cancer 
related deaths (11) and is projected to become the second leading cause of cancer deaths 
by 2030 (2). PDAC is often undiagnosed until it has metastasized and these advanced 
tumors display resistance to existing therapeutic modalities. Although there have been 
recent improvements in combination chemotherapies such as Nab-Paclitaxel/Gemcitabine 
and FOLFIRINOX (145, 146), the overall 5-year survival rate has not exceeded 8% (11). 
Furthermore, PDAC has a well-characterized mutational profile that plays a key role in 
disease onset and progression (>90% cases with KRAS mutations and >50% with 
inactivating mutations in p53, CDKN2A, or SMAD4) (147), but the knowledge of these 
genetic perturbations has yet to yield targeted therapies. The lack of effective treatments 
and early detection necessitates the critical need to further dissect molecular mechanisms 
associated with PDAC progression to develop novel and effective therapeutic strategies 
for improving patient survival. 
Autophagy is the process in which cells degrade internal constituents for the 
maintenance of cellular homeostasis and survival under stress conditions (42). When 
autophagy is induced, cytoplasmic components are sequestered into double-membrane 
vesicles called autophagosomes, which then fuse with lysosomes. Subsequently, the 
hydrolases of the lysosomal compartments degrade cytoplasmic cargo and release the 
 73 
basic cellular building blocks into the cytosol for recycling (42). Recent studies document 
that the upregulation of autophagy can serve as a survival mechanism in various 
malignancies (39-41, 53-61), including PDAC tumor growth and progression (39-41). 
These reports have paved the way for therapies in clinical trials for PDAC patients that 
feature HCQ, a lysosomotropic agent that inhibits autophagy (clinicaltrials.gov 
NCT01273805). However, HCQ is associated with toxicity and off-target effects such as 
neuromyotoxicity (65), retinopathy (62, 63), and cardiomyopathy (64, 148). 
Increasing evidence suggests that miRNA-based therapeutics have limited off-
target effects and could emerge as novel therapeutic agents for various human diseases 
including cancer (139, 140, 142, 149-152). miRNAs are conserved small non-coding 
RNAs, that regulate post-transcriptional gene expression (66, 153). These small 
molecules are abundantly expressed in normal tissue, and are often missregulated in 
disease states. Restored expression of downregulated miRNAs has been suggested to be 
beneficial in therapeutically targeting cancer (136, 154, 155). We and others have found 
miR-29 to be downregulated in PDAC (85, 156, 157). Of importance, overexpression of 
miR-29 in stromal cells reduced the accumulation of stromal proteins and cancer colony 
formation in direct co-cultures (85). 
In this study, we address the role of miR-29 in autophagy in pancreatic cancer 
cells. We found downregulation of miR-29 in a range of pancreatic cancer cell lines, and 
restored expression of miR-29a blocked autophagy flux by inhibiting expression of key 
autophagy proteins, TFEB and ATG9A. Furthermore, miR-29a overexpression sensitized 
chemoresistant pancreatic cancer cells to gemcitabine and reduced their invasive 
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potential. Our findings provide evidence for the use of miR-29a as a novel therapeutic 
agent to thwart autophagy and target PDAC.  
 
3.2 Materials and Methods 
Cell lines  
Normal human pancreatic epithelial cell lines HPNE (ATCC, CRL-4023) and 
HPDE (AddexBio, T0018001) were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies, 11965-092) supplemented with 10% fetal bovine serum 
(FBS). Panc-1 (ATCC, CRL-1469) and MIA PaCa-2 (ATCC, CRL-1420) were grown in 
DMEM supplemented with 10% FBS, 100units ml-1 penicillin, and 100mg ml-1 
streptomycin. COLO 357 (158), AsPC-1 (ATCC, CRL-1682), and BxPC-3 (ATCC, 
CRL-1687) were grown in Roswell Park Memorial Institute (RPMI) 6140 (Life 
Technologies, 11875-093) supplemented with 10% FBS, 100units ml-1 penicillin, and 
100mg ml-1 streptomycin. 
RNA purification  
 Total RNA was extracted from cells using Trizol extraction kit (Life 
Technologies, 15596018) according to the manufacturer’s protocol. The quantity and 
purity of RNA was determined by OD260/280 reading using a Nanodrop 
spectrophotometer.   
Measurements of RNA by qPCR  
 Mature miR-29 family member expression and p62 mRNA expression 
levels were measured by TaqMan Assays (Applied Biosystems): miR-29a (ID:002112); 
miR-29b (ID:000413); and miR-29c (ID:000587) ; and SQSTM1/p62 (ID: 4331182). U6 
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snRNA (ID:001973) or ACTB (ID: 4331182) were used as a endogenous controls to 
normalize miR-29 expression and p62 expression respectively. Samples were analyzed 
using ABI 7500 Real-Time PCR machine. Samples were run in triplicates with 0.2 
thresholds, and the ΔΔCT method was used for relative miR-29 expression analysis.  
Western blot analyses of proteins  
Total cell protein was isolated using RIPA buffer (Thermo Scientific, PI-89900) 
and quantified using BCA Protein Assay Kit (Pierce Biotechnology, 23225). Protein were 
separated by SDS-PAGE and were transferred to polyvinylidene fluoride membrane.  
Membranes were incubated in a solution of 10% dried non-fat milk, and then probed with 
primary antibodies against Caspase-3 (Novus Biological, 9662S), Procaspase-3 (Cell 
Signaling, 9662S), LC3B (Novus Biological, NB100-2220), SQSTM1/p62 (Thermo 
Scientific, H00008878-M01), LAMP-2 (Santa Cruz, sc-18822), ATG9A (ab108338), 
TFEB (Cell Signaling, 4240), or GAPDH (Millipore, MAB374).  The membranes were 
then incubated with corresponding HRP conjugated goat anti-rabbit (Santa Cruz, sc-
2004), goat anti-mouse (Bio-Rad, 172-1011), or donkey anti-goat (Santa Cruz, sc-2020) 
secondary antibodies. Proteins were visualized and quantified using chemiluminescent 
detection kit (GE Healthcare, Amersham ECL) and exposed to x-ray film (Thermo 
Scientific, CL-X Posure Film) or captured on an Amersham Imager 600 (GE Healthcare, 
CCD Model). The intensity for each band was densitometrically quantified and 
normalized against loading control using ImageJ software. 
Transfection of cultured cells  
Exponentially growing cancer cells were seeded in 6 well plates at 1x105 cells per 
well or 12 well plates at 5x104 per well and allowed to adhere overnight and transfected 
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with indicated concentrations (10 µM, 20 µM) of control (GE Dharmacon, CN-001000-
01) or miR-29a (GE Dharmacon, C-300504-07) mimics, or 1 µM siRNA using siCTRL 
(GE Dharmacon, D-001810-10-05), siTFEB (GE Dharmacon, L-009798-00-0005), and 
siATG9A (GE Dharmacon, L-014294-01-0005) using DharmaFECT®1 (GE Dharmacon, 
T-2001-01) as per the manufacturer’s protocol. Total protein or RNA was isolated at 24 
hours post-transfection for western blot or qPCR analysis respectively as described 
above. 
Migration and invasion measurements  
1x104 cells (Panc-1 or MIA PaCa-2) transfected with 20 nM control or miR-29a 
mimics using DharmaFECT®1 were plated in triplicate in the upper chambers of 8 µm 
transwells (Falcon, 353097) in 100 µl serum-free media and 750 µl 10% serum 
containing media in the lower chamber of 24-well plates and incubated at 37°C for 24 
hours. For invasion assays, 80 µl of 1:5 diluted matrigel (BD, 354234) was pre-coated in 
the upper chambers and allowed to solidify prior to plating cells. 24 hours post-seeding, 
membranes were washed twice with PBS, fixed with 4% paraformaldehyde, and stained 
with 0.1% crystal violet in 20% ethanol. Cells remaining in the upper chamber were 
carefully removed, and cells migrated/invaded on to the lower membrane were imaged 
and counted. For each well, 5 random fields were counted, and average number of cells 
per field was presented.   
Measurements of cell viability, cytotoxicity, and caspase activity  
5x103 pancreatic cancer cells per well (Panc-1, MIA PaCa-2, or COLO 357) were 
plated in 96 well plates and grown at 37°C for 24 hours. Cells were then transfected with 
20 nM mimic control or miR-29a mimic using DharmaFECT®1 for 24 
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hours. Transfection media was then removed and replaced with complete media, and cells 
were allowed to recover for 24 hours and subsequently treated with varying 
concentrations of gemcitabine (0 µM, 0.1 µM, 1 µM, 10 µM, 100 µM). Cell viability was 
measured at 72 hours post-gemcitabine treatment by adding 10µl Cell Counting Kit-8 
(CCK8) reagent (Dojindo, CK04) and absorbance was measured at 450 nm. For cell 
viability with Chloroquine (CQ) and BafilomycinA1 (BafA1) treatment, cells were 
treated with 25 µM CQ (Sigma Aldrich, C6628) or 10 µM BafA1 (Sigma Aldrich, 
B1793) in combination with 10 µM gemcitabine for 48 hours, and viability was measured 
using CCK8 kit as described above. For cytotoxic effects and caspase activity, pancreatic 
cancer cells (Panc-1, MIA PaCa-2) were transfected with mimic control or miR-29a 
mimic as described above and treated with 10 µM gemcitabine for 24-48 hours. For 
cytotoxic effects, lactate dehydrogenase release was determined using Promega CytoTox-
ONE Homogeneous Membrane Integrity Assay (Promega, G7890) and fluorescence was 
measured at 560/590 nm. Caspase activity was determined using Promega Apo-ONE 
Homogenous Caspase-3/7 Assay Kit (Promega, PRG7790) with fluorescence measured at 
490/530 nm. 
Soft agar assays  
3x105 pancreatic cancer cells per well (Panc-1 or MIA PaCa-2) were plated in 6 
well plates and grown at 37°C for 24 hours. Cells were then transfected with 20 nM 
mimic control or miR-29a mimic using DharmaFECT®. 1.5x103 pancreatic cancer cells 
(Panc-1 or MIA PaCa-2) transfected with control or miR-29a mimcs were plated per well 
in a 6 well plate containing 0.5% top agarose and 1% bottom agarose (BioRad, 162-
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0137). After 20 days, colonies were stained with crystal violet and were counted under 
low power bright field microscopy for positive colonies. 
Luciferase reporter assay  
The 3’-UTR containing predicted miR-29 binding sites, both wild type and 
mutant, for ATG9A and TFEB were cloned into pmirGLO Dual-Luciferase miRNA 
Target Expression Vector (Promega, #E1330) downstream of the firefly luciferase open 
reading frame. 5x103 pancreatic cancer cells per well (Panc-1 or MIA PaCa-2) were 
plated in 96 well plates and grown at 37°C for 24 hours. Cells were then co-transfected 
10 nM mimic control or miR-29a mimic with 100 ng of pmirGLO Dual-Luciferase 
miRNA Target Expression Vector containing each respective 3’-UTR binding site using 
DharmaFECT Duo Transfection Reagent (GE, T-2010-02). Cells were transfected for 24 
hours, and luciferase levels were measured 24 hours post-transfection using Dual-Glo® 
Luciferase Assay System (Promega, #E2920). Firefly luciferase luminescence was 
normalized to renilla luciferase activity for each transfected well.  
Autophagy assays  
For assessment of miR-29 effects on autophagy flux via immunoblotting, 1x105 
pancreatic cancer cells per well (Panc-1, MIA PaCa-2, or COLO 357) were plated in 12 
well plates and grown at 37°C for 24 hours. Cells were then transfected with 10 nM 
control or miR-29a mimics using DharmaFECT®1. 24 hours post-transfection, cells were 
treated with 25 µM CQ in complete media for 3-6 hours. Subsequently, total proteins 
were harvested and subjected to western blot analysis as described above. Lentivirus 
encoding GFP-LC3B were generated using plasmid (GeneCopoepia, EX-T0824-Lv103) 
in HEK293 cells (ATCC, CRL-1573) via standard HEPES/Calcium Phosphate 
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transfection. Stable Panc-1 GFP-LC3B cells were generated by transducing exponentially 
growing Panc-1 cells in T-75 flask. GFP positive cells were selected by flow cytometry 
and were expanded for one week prior to conducting experiments. For 
immunofluorescence imaging, cells were fixed with 4% PFA and permeabilized using 
0.1% triton and blocked using 1% BSA. Primary LAMP-2 antibody (Santa Cruz, 
SC18822) was incubated overnight, followed by secondary Alexa Fluor® 647 antibody 
(Abcam, ab150079) incubation and 10ug/mL Hoechst Nuclear Stain (Life Technologies, 
ab150083). Eight 0.5 micron Z-stack sections were captured using the Opera (Perkin 
Elmer) fluorescent microscope and final images were deconvolved and analyzed using 
Volocity imaging analysis software (Perkin Elmer). Quantifications for number of GFP-
LC3B positive compartments and colocalization of GFP-LC3B and LAMP-2 were taken 
from 4 random fields with 8-10 cells per field.  
Statistics  
ANOVA with Tukey’s post-hoc test and 2-tailed Student’s t tests were used to 
test for statistical significance. P < 0.05 was considered statistically significant. 
 
3.3 Results 
miR-29a sensitizes chemotherapeutic resistant pancreatic cancer cell lines to gemcitabine 
treatment.  Previously, we observed a global and epithelial-specific decrease in miR-29 
expression in the pancreata of a well-characterized pancreatic cancer mouse model, LSL-
KRasG12D; Pdx1Cre, and human PDAC patients (85). To understand the function of miR-
29 in pancreatic cancer cells, we initially measured the expression levels of miR-29 in 
five pancreatic cancer cell lines (Panc-1, MIA PaCa-2, COLO 357, BxPC-3, and AsPc-1) 
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compared to two normal human pancreatic ductal epithelial cell lines (HPNE and HPDE). 
There was a significant decrease in miR-29a and miR-29b expression in four out of five 
pancreatic cancer cell lines compared to normal human pancreatic ductal epithelial cells 
and levels of miR-29c were lower in three out of five pancreatic cancer cell lines (Figure 
26A). We have previously reported that miR-29a is the most abundantly expressed miR-
29 family member in the human pancreas and in pancreatic stellate cells (85) and also 
found that miR-29a is the most highly expressed miR-29 family member in the normal 
human pancreatic epithelial cell line, HPNE (Figure 27). Therefore, we focused on miR-
29a for functional studies. 
One of the major limitations in treating PDAC is that cancer cells acquire resistance 
to existing chemo and radiation therapeutic modalities, including gemcitabine (159). 
Furthermore, pancreatic cancer cells are surrounded by dense fibrotic stroma, which is 
known to impair drug delivery to the tumor core (21). Previously, we showed that 
overexpression of miR-29a in pancreatic stellate cells, the major stromal cells responsible 
for fibrotic stroma, reduced extracellular matrix protein accumulation and cancer growth 
in co-cultures, suggesting its potential use as a novel therapeutic agent in normalizing 
stromal abundance to target PDAC (85).  To test the feasibility of combining miR-29a 
with gemcitabine, a standard therapy, we investigated the effect of miR-29a 
overexpression on viability of known gemcitabine resistant pancreatic cancer cell lines, 
Panc-1 and MIA PaCa-2 (160). Overexpression of miR-29a alone did not significantly 
reduce the viability of cancer cells, but the addition of gemcitabine resulted in a 
significant decrease at various concentrations starting at 0.1 µM (Figure 26B). 
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Furthermore, miR-29a did not have any additive effect on cell viability in gemcitabine 
sensitive PDAC cell line, COLO 357 (161), to drug treatment (Figure 28). 
Evasion of cell death is a crucial event during malignant transformation of pancreatic 
cancer cells. Initially, we determined the cytotoxic effects of miR-29a in combination 
with gemcitabine on PDAC cell lines resistant to gemcitabine (Panc-1 and MIA PaCa-2) 
by measuring the release of lactate dehydrogenase (LDH) (162, 163). There was a 
significant increase in LDH from the Panc-1 and MIA PaCa-2 cells overexpressing miR-
29a upon gemcitabine treatment, indicating that miR-29a increases cytotoxicity in 
combination with gemcitabine (Figure 26C, Figure 29). We also observed increased 
caspase 3/7 activity (Figure 26D, Figure 30A) and cleaved caspase-3 levels (Figure 26E, 
Figure 30B) in miR-29a overexpressing cancer cells upon gemcitabine treatment 
compared to cancer cells treated with gemcitabine alone. Taken together, these findings 
indicate that miR-29a sensitizes pancreatic cancer cells to gemcitabine treatment and 
provides compelling evidence for its use in combination with gemcitabine as a novel 
therapeutic strategy to target PDAC. 
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Figure 26. miR-29a increased sensitivity of chemoresistant PDAC cells to 
gemcitabine treatment. (A) qPCR analysis of miR29 family members in normal human 
ductal epithelial cell lines (HPNE and HPDE) and pancreatic cancer cell lines (Panc-1, 
MIA PaCa-2, COLO 357, BxPC-3, AsPC-1) (n=4). Data represented as average fold 
change (ΔΔCT) ± standard error of the mean (S.E.M.) (B) Pancreatic cancer cell lines 
(Panc-1 and MIA PaCa-2) were seeded into 96-well plates, transfected with control 
(CTRL) or miR-29a mimics, treated with indicated concentrations of gemcitabine (GEM) 
for 24 hours post-transfection, and viability was measured at 72 hours post-treatment 
using the Cell Counting Kit-8 (CCK-8) as a measure of viability. Average absorbance 
(A450) is represented (n=8) ± S.E.M. (C) Panc-1 cells were transfected with CTRL or 
miR-29a mimics, treated with 10µM GEM for 48 hours and lactate dehydrogenase (LDH) 
release was determined by substrate based activity assay (fluorescence 560/590 nm). 
Average relative percent cytotoxicity are represented (n=3-4) ± S.E.M. (D) Panc-1 cells 
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were transfected with CTRL or miR-29a mimics. 24 hours post-transfection cells were 
treated with 10µM GEM for 24 hours, lysed, and caspase activity was determined by 
absorbance using Apo-ONE Homogeneous Caspase-3/7 Assay according to 
manufacturer’s protocol. Average relative fluorescence (RFU, 490/530 nm) are 
represented (n=4) ± S.E.M. (E) Panc-1 transfected with CTRL or miR-29a mimics, 
treated with 10µM GEM for 12 hours and 15 µg of total cell protein lysate was subjected 
to western blot analysis for procaspase-3, cleaved caspase-3, and GAPDH was used as 
loading control. Relative quantification of band intensities normalized to GAPDH are 
shown below respective blots. All experiments were repeated 3-4 times and 
representative data is presented. *p<0.05, **p<0.01, non-significant (n.s.). 
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Figure 27. miR-29a is the most abundantly expressed miR-29 family member in 
human pancreatic normal epithelial cell line. RNA was isolated from human 
pancreatic normal epithelial cells (HPNE) (n=3) and miR-29a, -29b, and -29c expression 
levels were determined by qPCR analysis using U6 snRNA as an internal control. Delta 
CT (ΔCT) was calculated for each miR-29 family member to measure relative expression 
levels. Boxplots represent -1/ΔCT of miR-29 family expression levels. *p<0.05.   
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Figure 28. Effect of miR-29a overexpression and gemcitabine treatment on COLO 
357 cell viability. COLO 357 were seeded into a 96-well plate, transfected for 24 hours 
with CTRL or miR-29a mimics, and treated with various concentrations of gemcitabine, 
and cell viability was measured at 72 hours post-treatment using the Cell Counting Kit-8 
(CCK-8) assay according to manufacture’s protocol. Average relative absorbance (A450) 
is presented (n=6) ± Standard Error of the Mean (S.E.M.).  
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Figure 29. LDH release in MIA PaCa-2 cells treated with gemcitabine in 
combination with miR-29a. MIA PaCa-2 cells were transfected with CTRL or miR-29a 
mimics, treated with gemcitabine (GEM) for 48 hours and lactate dehydrogenase (LDH) 
release was determined by substrate based activity assay (fluorescence 560/590 nm). 
Average relative percent cytotoxicity is represented (n=4) ± S.E.M. 
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Figure 30. Caspase3/7 activity and activated caspase 3 levels in MIA PaCa-2 cells 
treated with gemcitabine in combination with miR-29a. MIA PaCa-2 cells were 
transfected with CTRL or miR-29a mimics. (A) Transfected cells were treated with 
10µM gemcitabine (GEM) for 24 hours, lysed, and caspase activity was determined using 
Apo-ONE Homogeneous Caspase-3/7 Assay. Average fluorescence (490/530 nm) is 
represented (n=4) ± S.E.M. (B) Transfected cells were treated with 10µM GEM for 12 
hours. Post GEM treatment, 15 µg of total protein lysate was subjected to western blot 
analysis for quantitation of pro-caspase 3 and cleaved caspase 3. GAPDH was used as 
loading control for the western blot. Relative quantification of band intensities 
normalized to GAPDH is shown below respective blots. 
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miR-29a inhibits autophagy flux in pancreatic cancer cells. Pancreatic cancer cells induce 
autophagy as a survival mechanism to escape gemcitabine induced cell death (39, 60, 61). 
Therefore, we sought to determine the effect of miR-29 on autophagy, to assess whether 
the increased sensitivity and cytotoxic effects of gemcitabine in chemotherapeutic 
resistant pancreatic cancer cells is due to alterations in autophagy. LC3B is a widely used 
marker to monitor autophagy levels (164). Normally, LC3B resides in the cytoplasm 
(LC3BI), and upon initiation of autophagy, it is conjugated with phosphatidyl-
ethanolamine (LC3BII) to facilitate formation and expansion of the autophagosome 
membrane (165-169).  
To elucidate the effects of miR-29a on PDAC autophagy, Panc-1 cells, which have 
high basal levels of autophagy (39), were transfected with miR-29a or mimic control and 
LC3B levels were assessed by western blot analysis. There was a marked increase in 
LC3B upon miR-29a overexpression in Panc-1 cells (Figure 31A). Similar observations 
were found in MIA PaCa-2 and COLO 357 cells (Figure 32). An increase in LC3B levels 
can indicate an upregulation of autophagy or a blockage of autophagy flux (170). We 
therefore examined the expression of an autophagic substrate, p62, in conjunction with 
LC3B. p62/SQSTM1 is efficiently degraded upon autophagy induction and serves as an 
indicator of autophagic turnover (170). An increase in p62 levels correlates with an 
inhibition in autophagy, whereas a decrease indicates induction of autophagy (171). 
There was a robust accumulation of p62 in miR-29a overexpressing cancer cells (Figure 
31, Figure 32), suggesting that miR-29a causes a late stage blockage in autophagy flux. It 
is possible that the increase in p62 could be due to an indirect transcriptional upregulation 
rather than inhibition of autophagy. Therefore, we measured p62 transcript levels and 
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found no significant change (Figure 33), indicating that p62 accumulation is due to a 
perturbation in autophagy. 
Chloroquine (CQ) is a lysosomotropic agent that inhibits autophagy by raising 
lysosomal pH (172). The increase in lysosomal pH permits autophagosome-lysosome 
fusion but prevents degradation and autolysosomal turnover (173).  To further assess the 
effect of miR-29a on autophagy flux, miR-29a or mimic control was transiently 
expressed in Panc-1 cells and then treated with CQ. Our results showed a net increase in 
LC3BI and II and p62 accumulation in control cells upon CQ addition. However, when 
miR-29a is overexpressed, prior to CQ treatment, the amount of LC3B and p62 in cells 
subjected to a combination of miR-29a and CQ combination was as low as miR-29a 
alone, supporting the idea the miR-29a had already blocked autophagy (Figure 31A). 
These results were further recapitulated in MIA PaCa-2 and COLO 357 cells (Figure 32). 
Similar to CQ, BafilomycinA1 (BafA1) functions as a late stage inhibitor of autophagy 
by raising lysosomal pH (174) and also blocks autophagosome-lysosome fusion (175). 
Treatment of Panc-1 and MIA PaCa-2 with other late stage autophagy inhibitors, CQ and 
BafA1, resulted in p62 and LC3B accumulation similar to miR-29a overexpression 
(Figure 34).  
Pancreatic cancer cells have been previously shown to induce autophagy and acquire 
resistance to chemotherapy (41, 176, 177). To verify the functional effect of miR-29a 
mediated blockage of autophagy flux on gemcitabine sensitization, we evaluated the 
effects of miR-29a on cancer cell viability in comparison with BafA1. Similar to miR-29, 
treatment of cancer cells with gemcitabine in combination with BafA1 decreased cancer 
cell viability (Panc-1 and MIA PaCa-2) compared to gemcitabine alone (Figure 31B, 
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Figure 35). To further elucidate the effect of miR-29a and gemcitabine combination on 
pancreatic cancer cell autophagy, miR-29a expressing Panc-1 and MIA PaCa-2 cells were 
treated with gemcitabine and LC3B and p62 proteins were measured by western blot 
analysis (Figure 36). Similar to previous reports of gemcitabine induced autophagy in 
cancer cells (176, 178), Panc-1 and MIA PaCa-2 cells treated with gemcitabine alone 
exhibited a marked increase in LC3BII and decrease in p62, indicating autophagy 
induction. However, miR-29a overexpressing cancer cells did not exhibit any net 
decrease in p62 with an increase in LC3B levels upon gemcitabine treatment due to a 
miR-29a mediated inhibition of autophagy (Figure 36). Taken together, these findings 
suggest that miR-29a functions as an inhibitor of late stage autophagy, which serves to 
sensitize chemoresistant pancreatic cancer cell lines (Panc-1 and MIA PaCa-2) to 
gemcitabine treatment.   
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Figure 31. miR-29a overexpression causes blockage in autophagy flux. (A) Panc-1 
cells were transfected with CTRL or miR-29a mimics. Following transfection, cells were 
treated with 25µM chloroquine (CQ) and 5 µg of total protein lysates were subjected to 
western blot analysis to measure p62 and LC3B. GAPDH was used as loading control. 
Quantification of band intensities normalized to GAPDH is shown below the respective 
blots. (B) Panc-1 cells were transfected with CTRL or miR-29a mimics and treated with 
and without 10µM GEM. In parallel, Panc-1 cells were treated with 10µM GEM alone or 
in combination with 10µM BafA1. 48 hours post GEM treatment, cell viability was 
determined using CCK-8 assay kit. Average relative absorbance (A450) normalized to 
respective controls is presented (n=6) ± S.E.M. All experiments were repeated 3-4 times 
and representative data is presented. *p<0.05, **p<0.01, and ***p<0.001. 
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Figure 32. Overexpression of miR-29a inhibits autophagic flux in MIA PaCa-2 and 
COLO 357 cells. (A) MIA PaCa-2 or (B) COLO 357 pancreatic cancer cells were 
transfected with CTRL or miR-29a mimics. 24 hours after transfection, cells were treated 
with 25 µM chloroquine (CQ) for 3 hours and total protein was harvested. 5 µg of total 
protein lysate was subjected to western blot analysis for quantitation of p62 and LC3B. 
GAPDH was used as loading control. Quantification of protein band intensities 
normalized to GAPDH is shown below respective blots. 
 
 
 
 
 
 93 
 
Figure 33. p62 mRNA expression is unaltered by miR-29a overexpression in Panc-1 
and COLO 357 cells. (A) Panc-1 or (B) COLO 357 pancreatic cancer cells were 
transfected with CTRL or miR-29a mimics (n=3). 24 hours after cell transfection, total 
RNA was harvested and the levels of p62 gene transcripts were measured by qPCR. 
ACTB mRNA was used as an endogenous control. The measurments are represented as 
average fold change (ΔΔCT) ± S.E.M. 
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Figure 34. Effect of CQ and BafA1 on Panc-1 and MIA PaCa-2 autophagy. (A) 
Panc-1 or (B) MIA PaCa-2 cells were treated with either 25µM chloroquine (CQ) or 
10µM bafilomycinA1 (BafA1) for 6 hours. Cells were lysed and. 5 µg of total protein 
was analyzed by western blot analysis to measure p62 and LC3B proteins. GAPDH was 
used as loading control. Quantification of protein band intensities normalized to GAPDH 
are shown below respective blots. 
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Figure 35. Effect of miR-29a, CQ, and BafA1 on sensitization of MIA PaCa-2 cells 
to gemcitabine treatment. MIA PaCa-2 cells were transfected with CTRL or miR-29a 
mimics and treated with 10µM gemcitabine (GEM). In parallel, MIA PaCa-2 cells were 
treated with 10µM GEM alone or in combination with 25µM CQ or 10µM BafA1. 48 
hours post GEM treatment, cell viability was determined using CCK-8 assay kit. Average 
relative absorbance (A450) normalized to respective controls is presented (N=6) ± S.E.M. 
***p<0.001. 
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Figure 36. miR-29a blocks gemcitabine induced autophagy in Panc-1 and MIA 
PaCa-2. (A) Panc-1 or (B) MIA PaCa-2 cells transfected with CTRL or miR-29a mimics, 
were treated with or without 10µM GEM and 5 µg of total protein lysates were subjected 
to western blot analysis to measure p62 and LC3B proteins. GAPDH was used as loading 
control. Relative quantification of band intensities normalized to GAPDH are shown 
below respective blots. 
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miR-29a inhibits autophagosome-lysosome fusion.  During autophagy, autophagosomes 
fuse with lysosomes where lysosomal hydrolases degrade the autophagosomal contents, 
which are recycled back into the cytoplasm (42). To understand the mechanisms by 
which miR-29a mediates blockage of autophagy flux, we evaluated its impact on 
autophagosomes and their interactions with lysosomes. Panc-1 cells stably expressing 
GFP-LC3B were transfected with miR-29a or control mimics, treated with 25 µM CQ, 
and stained with lysosomal-associated membrane protein 2 (LAMP-2), a lysosomal 
marker. In subsequent image analysis, we observed a two-fold increase in accumulation 
of autophagosomes/autophagolysosomes in miR-29a overexpressing cells (Figure 37A, 
Figure 37B, Figure 38, Figure 39). Furthermore, overexpression of miR-29a resulted in a 
>35% decrease in LC3B/LAMP-2 colocalization at basal levels and >60% decrease in 
miR-29a overexpressing cells treated with CQ, compared to CQ alone (Figure 37A, 
Figure 37C, Figure 39), indicating that miR-29a mediated blockage of autophagosome-
lysosome fusion.  
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Figure 37. miR-29a inhibits autophagosome-lysosome fusion. (A) Panc-1 stably 
expressing GFP-LC3B were transfected with CTRL or miR-29a mimics. Following 
transfection, cells were treated with 25µM CQ. Cells were fixed and stained for 
lysosomal-associated membrane protein 2 (LAMP-2). (B) Image analysis was conducted 
to quantify number of GFP-LC3B positive compartments per cell, and averages are 
presented ± S.E.M. (C) Colocalization of GFP-LC3B and LAMP-2 was calculated based 
on the percentage of colocalization ± S.E.M. Experiment was repeated 3 times and 
representative data is presented. *p<0.05, **p<0.01, nonsignificant (n.s.). 
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Figure 38. LC3B puncta quantification in miR-29a overexpressing Panc-1 cells. 
GFP-LC3B stable Panc1 cells were transfected with CTRL or miR-29a mimics. 
Following transfection, cells were treated with 25µM CQ for 3 hours, fixed, and imaged. 
Number of GFP-LC3B positive puncta was counted and average number of GFP-LC3B 
positive puncta per cell (N>25 cells/group) is presented ± S.E.M (n=3). Representative 
images are shown below each graph. *p<0.05, non-significant (n.s.). 
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Figure 39. 2D representative images of LC3B and LAMP-2 colocalization in miR-
29a overexpressing Panc-1 cells. GFP-LC3B stable Panc-1 cells were transfected with 
CTRL miRNA or miR-29a mimics. Following transfection, cells were treated with 25µM 
CQ for 3 hours, fixed, and stained for the LAMP-2 lysosomal marker (60x 
magnification). GFP-LC3B and LAMP-2 are presented, along with a merged image.  
Scale bar indicates 20µm. 
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miR-29a downregulates critical autophagy proteins TFEB and ATG9A. To address the 
mechanisms by which miR-29a mediates blockage of autophagy at late stages, we 
searched for potential autophagy related genes that are targeted by miR-29a using four 
prediction algorithms (TargetScan, PicTar, PITA, and miRanda). We found that both 
transcription factor EB (TFEB) and autophagy-related protein 9A (ATG9A) contain 
phylogenetically conserved miR-29 binding sites in their 3’-UTRs (Figure 40A). TFEB is 
a transcription factor and member of the MiT/TFE family, which has been shown to be an 
integral part of the lysosome and autophagy machinery (179). Upregulation of MiT/TFE 
factors has been implicated in various cancers (180-182), and a recent study documented 
that upregulation of TFEB contributes to increased autophagy in PDAC (182). 
Furthermore, knockdown of TFEB impaired growth and metabolism of PDAC cells by 
disrupting lysosomal catabolism in autophagy (182). Among >30 essential autophagy-
related (ATG) genes (183), ATG9A is the only transmembrane protein (184) and has 
been shown to facilitate trafficking lipid membrane from the Golgi network and 
endosomes to the formation of autophagosomes (185, 186). Expression of ATG9A has 
been shown to be increased in some carcinomas (187, 188), but it has yet to be studied in 
PDAC. In our western blot analysis, overexpression of miR-29a in pancreatic cancer cells 
resulted in a marked repression of both TFEB and ATG9A expression (Figure 40B, 
Figure 41). As miRNAs regulate the expression of multiple target mRNAs, we wished to 
confirm that miR-29a does not alter expression of GAPDH, our endogenous control.   We 
conducted target prediction analysis (Targetscan) and confirmed that GAPDH is not a 
target of miR-29a (data not shown), and we did not detect changes in Ct values for 
GADPH mRNA levels upon transfection of the miR-29a compared to control.  These 
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findings help to insure that GAPDH was a proper loading control in our western blot 
analysis. 
As we observed downregulation of TFEB and ATG9A in response to miR-29a 
overexpression, we next wished to address whether miR-29a directly repressed the 
expression of TFEB and ATG9A mRNAs. Luciferase reporter plasmids were constructed 
that included the 3’-UTR for both gene transcripts.  Both 3’-UTRs contain predicted 
miR-29 binding sites. Wild type and mutated versions of the predicted miR-29a binding 
sites (Figure 40A) were include in the 3’-UTR downstream of the luciferase open reading 
frame. When reporter plasmids with wild type miR-29a binding sites were co-transfected 
with miR-29a mimics into cancer cells, there was a significant repression of luciferase 
activity. However, when the 3’-UTRs were mutated, miR-29a no longer has the ability to 
repress luciferase activity of the reporters with the TFEB and ATG9A 3-UTRs.  These 
findings indicate that miR-29a represses TFEB and ATG9A expression by directly 
interacting with the predicted sites 3’-UTR sites in both autophagy genes. Consistently, 
we observed higher ATG9A and TFEB expression in pancreatic cancer cells that have 
low miR-29a expression (Panc-1 and MIA PaCa-2), compared to normal pancreatic 
epithelial cell line (HPNE) and cancer cell line with high miR-29 expression (AsPC-1) 
(Figure 42). Taken together, our data indicates that miR-29a downregulates TFEB and 
ATG9A through direct interactions with the 3’-UTR binding sites.   
Next, we sought to determine the effects of TFEB and ATG9A depletion on PDAC 
autophagy using siRNA mediated knockdown of TFEB or ATG9A. Knockdown of these 
two genes resulted in an accumulation of LC3B and p62 similar to miR-29a 
overexpression (Figure 40D and Figure 43). Furthermore, knockdown of TFEB and 
 103 
ATG9A led to a significant increase in accumulation of GFP-LC3B positive vesicles 
(Figure 44). TFEB knockdown resulted in a ~50% increase of autophagosome 
accumulation, whereas ATG9A knockdown caused a >100% increase in autophagosome 
accumulation (Figure 44A, Figure 44B). Although knockdown of TFEB blocked 
autophagy as indicated by an increased accumulation in p62 and LC3B (Figure 44C). We 
did not find a significant difference in GFP-LC3B and LAMP-2 colocalization, 
suggesting that the increase in GFP-LC3B positive vesicles were mostly due to 
accumulation of autophagolysosomes (Figure 44A, Figure 44B). Whereas, knockdown of 
ATG9A resulted in a robust 2-fold decrease in colocalization of LC3B and LAMP-2, 
demonstrating that miR-29a inhibits autophagosome-lysosome fusion predominately by 
deregulation of ATG9A. Taken together, our results suggest that miR-29a inhibits 
autophagy flux through the downregulation of TFEB and ATG9A expression, which are 
critical for lysosomal function and autophagosome trafficking respectively.  
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Figure 40. miR-29a downregulates TFEB and ATG9A expression to inhibit 
autophagy. (A) Schematic representation of the miR-29 family members and 3’-UTR 
binding sites of miR-29 targets as well as mutated binding sites used in Luciferase 
Assays: Transcription Factor EB (TFEB) and Autophagy-related protein 9A (ATG9A). 
All three miR-29 family members (miR-29a, miR-29b, and miR-29c) have identical seed 
sequences. Conserved miR-29 binding sites in the 3’-UTR of mRNA transcripts encoding 
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ATG9A and TFEB are depicted in bold. (B) 10 µg of total protein lysates from Panc-1 
transfected with CTRL or miR-29a mimics were subjected to western blot analysis to 
measure the levels of TFEB, ATG9A, and GAPDH. Quantification of protein band 
intensities normalized to GAPDH are shown below each blot. (C) Relative firefly 
luciferase activity from reporter plasmid encoding TFEB or ATG9A 3’-UTRs following 
cotransfection into Panc-1 cells with control or miR-29a mimics.  For each, either wild 
type (WT) and mutant (mut) reporter constructs were analyzed. All readouts were 
normalized to renilla luciferase activity. Average relative luminesce normalized to 
respective controls is presented (n=6) ± S.E.M. (D) 5 µg of total protein lysates from 
Panc-1 cells that were transfected with CTRL, miR-29a mimics, siCTRL, siTFEB, or 
siATG9A. 24 hours post-transfection, total protein was harvested and subjected to 
western blot analysis for p62 and LC3B proteins. GAPDH was used as loading control. 
Quantification of the indicated protein bands, which were normalized to GAPDH and 
relative to control, are shown below respective blots. All experiments were repeated 3 
times and representative data is presented. 
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Figure 41. Effect of miR-29a overexpression on TFEB and ATG9A expression in 
MIA PaCa-2 and COLO 357 cells. (A) MIA PaCa-2 and (B) COLO 357 cells 
transfected with CTRL or miR-29a mimics. 10 µg total protein lysate was subjected to 
western blot to measure ATG9A and TFEB proteins. GAPDH was used as a loading 
control. Quantification of protein intensities normalized to GAPDH is shown below each 
blot. 
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Figure 42. ATG9A and TFEB expression in HPNE, Panc-1, MIA PaCa-2, and 
AsPC-1. Lysates were harvested from normal epithelial cells, HPNE, and cancer cell 
lines, Panc-1, MIA PaCa-2, and AsPC-1. 10 µg of total protein were analyzed by SDS-
PAGE and western blot analysis to measure ATG9A and TFEB proteins. GAPDH was 
used as loading control. Quantification of protein band intensities normalized to GAPDH 
is shown below each blot. 
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Figure 43. Effect of TFEB and ATG9A knockdown on autophagy of MIA PaCa-2 
cells. MIA PaCa-2 cells were transfected with CTRL miRNA or miR-29a mimics, or 
with siCTRL, siTFEB, or siATG9A. 24 hours after transfection, total protein was 
harvested and 5 µg of each was analyzed by western blot to measure the levels of p62 and 
LC3B proteins. GAPDH was used as loading control. Quantification of protein band 
intensities normalized to respective controls is shown below each blot. 
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Figure 44. Knockdown of TFEB and ATG9A results in decreased autophagosomal-
lysosomal fusion. (A) Panc-1 cells stably expressing GFP-LC3B were transfected with 
either CTRL miRNA or miR-29a mimics in cells in parallel with siCTRL, siTFEB, or 
siATG9A. Following transfection, cells were fixed and stained for lysosomal-associated 
membrane protein 2 (LAMP-2). (B) Image analysis was conducted to quantify number of 
GFP-LC3B positive compartments per cell, and averages are presented ± S.E.M. (C) 
Colocalization was calculated based on GFP-LC3B and LAMP-2 staining, and average 
percentage of colocalization is presented ± S.E.M. All experiments were repeated 3 times 
and representative data is presented. **p<0.05, **p<0.01, ***p<0.001 non-significant 
(n.s.). 
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miR-29a reduces pancreatic cancer cell invasion in vitro. Prior studies have also found 
that miR-29 is downregulated in a wide variety of carcinomas, including breast, 
colorectal, and prostate, and its reintroduction had anti-metastatic effects (112, 189, 190). 
Furthermore, increase in autophagy has been shown to enhance the invasive potential of 
cancer cells and promote epithelial-mesenchymal transition (EMT) (56, 57). As we 
observed downregulation of miR-29 in pancreatic cancer cells and its subsequent 
overexpression inhibited autophagy, we performed a series of in vitro functional studies 
to evaluate the effect of miR-29a on the invasive potential of pancreatic cancer cells. To 
determine the effect of miR-29a on cancer cell migration and invasion, Panc-1 and MIA 
PaCa-2 cells were transfected with control or miR-29a mimics and seeded in transwell 
assays. Compared to control cells, significantly fewer miR-29a overexpressing cancer 
cells migrated through transwell membranes and invaded through matrigel-precoated 
membranes (Figure 45, Figure 46).  
EMT is known to enhance the migration/invasion of pancreatic cancer cells and 
resistance to apoptosis (191-193). As miR-29 reduced the migration and invasion 
potential of pancreatic cancer cells, we sought to determine its effect on EMT. As 
expected, overexpression of miR-29a in pancreatic cancer cells increased expression of 
epithelial marker, E-cadherin (192) and decreased mesenchymal marker, Vimentin (192) 
(Figure 45C).  
 We next tested the effect of miR-29a overexpression on anchorage independent 
growth of pancreatic cancer cells using soft agar assays. There was a significant decrease 
in the number of anchorage independently growing cancer colonies in miR-29a 
overexpressing PDAC cells compared to cells expressing control mimic (Figure 46D, 
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Figure 47). Our results show that miR-29a induces an anti-invasive potential as illustrated   
by a reduction in migration, invasion, and anchorage independent growth of pancreatic 
cancer cells. 
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Figure 45. miR-29a inhibits invasive potential of PDAC cells. Panc-1 cells were 
transfected with control (CTRL) or miR-29a and plated into (A) migration and (B) 
invasion assays. Migration and invasion data were presented as average number of cells 
per 5 fields (n=3) ± S.E.M. and representative images shown below each graph. (C) 10 
µg of total cell lysates from Panc-1 transfected with CTRL or miR-29a mimics were 
subjected to western blot analysis for epithelial marker, E-cadherin, and mesenchymal 
marker, Vimentin, and GAPDH was used as loading control. Quantification of protein 
band intensities normalized to GAPDH is shown below each blot. (D) Panc-1 cells were 
transfected with CTRL or miR-29a mimics and plated into soft agar assays. Data 
presented as average number of colonies per well (n=6) ± S.E.M. and representative 
images are shown below each graph. All experiments were repeated 3-4 times and 
representative data is presented. *p<0.05, **p<0.01. 
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Figure 46. Effect of miR-29a overexpression on migration and invasion of MIA 
PaCa-2 cells. MIA PaCa-2 cells were transfected with control (CTRL) or miR-29a 
mimics and plated into (A) migration and (B) invasion assays. Migration and invasion 
data presented as average number of cells per 5 fields (n=3) ± S.E.M. with representative 
images below each graph. *p<0.05, **p<0.01. 
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Figure 47. Effect of miR-29a overexpression on anchorage independent growth of 
MIA PaCa-2 cells. MIA PaCa-2 cells were transfected with control (CTRL) or miR-29a 
mimics and plated into soft agar assays. Representative data is presented as average ± 
S.E.M. (n=3). Representative images are below each graph. *p<0.05. 
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3.4 Discussion 
Our study demonstrates for the first time that miR-29a functions as a potent 
autophagy inhibitor, and also sensitizes chemoresistant cancer cells to gemcitabine, and 
reduces the invasive potential of pancreatic cancer cells (Figure 48). There is an 
increasing body of evidence documenting a role for autophagy in cancer pathogenesis, 
supporting that idea that this pathway is a new therapeutic target (39-41, 53-59). We 
found consistent repression of miR-29 expression in pancreatic cancer cells, and 
overexpression of miR-29a inhibited autophagy, as illustrated by increased accumulation 
of autophagosomes/autophagolysosomes and autophagy markers, LC3B and p62. 
Furthermore, miR-29a decreased autophagosome-lysosome fusion, as shown by a 
significant decrease in colocalization of LC3B and LAMP-2, autophagosomal and 
lysosomal markers respectively. Taken together, our results suggest that miR-29a 
functions as a late stage autophagy inhibitor by blocking autophagosome-lysosome 
fusion.  
To determine the mechanisms of miR-29a mediated inhibition of autophagy, we 
identified two critical autophagy genes, TFEB and ATG9A, which have phylogenetically 
conserved miR-29 binding sites in the 3’-UTRs of their encoded transcripts. As expected, 
overexpression of miR-29a caused a marked reduction of TFEB and ATG9A expression. 
TFEB, a transcription factor essential for lysosomal function, is highly activated in 
PDAC (179) and its knockdown reduces tumor progression and impairs autophagy due to 
lysosomal dysfunction (182). ATG9A is the only transmembrane ATG protein, and 
facilitates membrane trafficking of autophagosomes (194, 195). Upregulation of ATG9A 
has been well documented in other carcinomas (187, 188). Knockdown of TFEB or 
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ATG9A caused a late stage blockage in autophagy similar to miR-29a overexpression.  
Interestingly, knockdown of ATG9A or TFEB increased the accumulation of LC3B 
positive compartments, but only the knockdown of ATG9A blocked autophagosome-
lysosome fusion.  As ATG9A functions in vesicular trafficking, reduced expression of 
ATG9A is likely to cause perturbations in autophagosome trafficking and prevent them 
from fusing with lysosomes. Whereas, TFEB knockdown mediated accumulation of 
autophagolysosomes is likely due to defective lysosomal degradation capacity rather than 
a blockage of autophagosome-lysosome fusion. Collectively, our results indicate that 
miR-29a inhibits PDAC autophagy by downregulation of TFEB and ATG9A.  
Pancreatic cancer acquires chemo-resistance by inducing autophagy (39-41). We 
found that miR-29a sensitized chemoresistant pancreatic cancer cells to gemcitabine 
treatment, decreased cancer cell viability, and enhanced gemcitabine-mediated 
cytotoxicity.  Accordingly, upon gemcitabine treatment, miR-29a overexpression resulted 
in an increased LDH release (162, 163), caspase 3/7 activity, and cleaved caspase 3.  CQ 
and BafA1 are known late stage autophagy inhibitors (172, 175). The effects of miR-29a 
on LC3B and p62 accumulation is similar to CQ and BafA1, suggesting that miR-29a 
serves as an effective late stage inhibitor of autophagy. miR-29 has been previously 
reported to induced cellular cytotoxicity/apoptosis by targeting anti-apoptotic protein 
Mcl-1 in cholangiocarcinoma (196). However, the effect of miR-29 on Mcl-1 and 
gemcitabine-mediated cytotoxicity is not known in pancreatic cancer cells. Further 
studies are required to dissect the role of Mcl-1 in this mechanistic axis.  
Our functional studies demonstrate that overexpression of miR-29a inhibits 
pancreatic cancer cell migration and invasion through reversion of cancer cell EMT. Prior 
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to metastasis, tumor cells undergo EMT, a process in which cells lose epithelial 
characteristics and gain a mesenchymal phenotype. A recent report suggested that EMT 
is a characteristic feature of malignant transformation that contributes to the 
invasive/metastatic properties of a wide variety of cancers (197).  Overexpression of 
miR-29a resulted in an increase in epithelial marker, E-cadherin, and reduction in 
mesenchymal marker, vimentin, indicating that reintroduction of miR-29a induces 
mesenchymal–epithelial transition (MET) in pancreatic cancer cells. However, vimentin 
is not a predicted miR-29 target (Targetscan), suggesting that miR-29a may induce MET 
transition through indirect effects rather than direct regulation of Vimentin. Of interest, 
autophagy has been shown to be concomitant with increased metastasis and EMT (56, 
57). Our findings demonstrate similar effects in which miR-29a mediated an inhibition of 
autophagy in tandem with MET transition and reduction of cancer cell invasive potential. 
It is possible that miR-29a reduces EMT in pancreatic cancer cells by inhibition of 
autophagy. However, further studies are warranted to dissect the precise underlying 
mechanisms.  
To further study the function of miR-29a, we investigated the effect of miR-29a on 
anchorage independent growth of pancreatic cancer cells. Epithelial cells require 
attachment to a substrate in order to maintain structural polarity, function, and survival 
(198). When this adhesion is lost, cells undergo anoikis, a form of programmed cell death 
induced by detachment (198, 199). Various cancers have been shown to avoid anoikis, 
leading to properties associated with metastasis and tumorigenesis (200). We found that 
overexpression of miR-29a significantly reduces the ability of pancreatic cancer cells to 
grow in an anchorage independent manner.  
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 With the exception of AsPc-1, we observed consistent downregulation of all three 
miR-29 family members in various pancreatic cancer cell lines. AsPC-1 contains 
homologous deletions in SMAD4, whereas the other cancer cell lines contain wildtype 
SMAD4 (201). SMAD4 is a major downstream effector molecule of TGF-β1 signaling, 
forms a heterogeneous complex with pSMAD2/3, and regulate the target gene expression 
(117). We and others demonstrated that TGF-β1 downregulates miR-29 expression in 
other cell types through SMAD2/3/4 complex (85, 202). Perhaps homologous deletion of 
SMAD4 in AsPC-1 derepresses miR-29 expression. However, this mechanism needs to 
be validated in PDAC.  Furthermore, the regulatory mechanism associated with 
downregulation of miR-29 has not been fully elucidated. The three miR-29 family 
members (miR-29a, -29b, -29c) are encoded from two co-transcribed miRNA clusters, 
miR-29a/b1 and 29c/b2 located on Chromosome 7 and 1 respectively. Both miR-29 loci 
have promoter regions containing c-Myc (203) and SMAD3 (202) binding sites. It would 
be of interest to determine if c-Myc or SMAD4 regulates miR-29 expression in 
pancreatic cancer cells, as both of them have been indicated to play a critical role in 
PDAC (204, 205).   
The downregulation and anti-tumorigenic effects of miR-29 have been reported in a 
wide variety of cancers (112, 189, 190). Furthermore, autophagy has been implicated in a 
number of carcinomas to promote metastasis (54) and induce chemoresistance (206-208). 
It would be of interest to evaluate the role of miR-29 in autophagy of other cancers, as 
this would shed light on whether the mechanism of autophagy inhibition that we have 
discovered is ubiquitous in cancer pathogenesis or idiosyncratic to pancreatic cancer. 
Furthermore, our findings need to be validated in vivo to translate our findings into the 
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clinic.  Nevertheless, our studies reveal a novel role of miR-29a in PDAC autophagy and 
provide evidence for its use as an autophagy inhibitor and novel therapeutic agent in 
combination with gemcitabine, to target PDAC. 
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Figure 48. Schematic diagram representing the role of miR-29a in PDAC autophagy 
and metastasis. miR-29a overexpression in pancreatic cancer cells decreases invasive 
potential and inhibits autophagy flux through downregulation of TFEB and ATG9A, 
resulting in increased sensitivity to GEM treatment. miR-29a may serve as a potential 
novel anti-autophagic/invasive agent to target PDAC. 
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Chapter 4: Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene 
Delivery in Normal and Pancreatic Cancer Mice 
4.1 Introduction 
The pancreas is a primary site of origin for a wide variety of diseases including 
diabetes, pancreatic cancer, and pancreatitis (209). PDAC has the worst prognosis among 
pancreatic diseases (210, 211). In the United States, it is the third leading cause of cancer 
deaths and is projected to become the second leading cause of cancer related deaths in 
just over a decade (2). Although combination chemotherapies such as Nab-
Paclitaxel/Gemcitabine and FOLFIRINOX (145, 146) modestly improves survival, the 
overall 5-year survival rate has not exceeded 8% for the last 30 years (212). Furthermore, 
PDAC has a well-characterized mutational profile that plays a key role in disease onset 
and progression (147), but the knowledge of these genetic perturbations has yet to yield 
effective, targeted therapies. A combination of novel gene/cell based therapeutic 
strategies with conventional chemo-radiation therapies may improve the survival rate of 
this deadly cancer. 
Pre-clinical animal models, particularly genetically engineered mouse models 
(GEMMs) of PDAC, have played a pivotal role in understanding the pathobiology of 
oncogenes/tumor suppressors and in developing new therapeutic strategies (113, 213-
217).  Importantly, large-scale deep sequencing data and The Cancer Genome Atlas 
(TCGA) are identifying new genetic aberrations associated with PDAC 
pathogenesis(218-220).  Developing pre-clinical mouse models for new oncogenic 
mutations and/or in combination with well-characterized genetic mutations associated 
with PDAC progression is a daunting process that typically takes several years.  Genome 
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editing tools such as CRISPR/Cas9 in combination with targeted gene delivery could 
serve as a potential surrogate to transgenic mouse models to study in vivo gene function 
(221-224). However, because of its anatomical location, targeted pancreatic gene delivery 
without safety concerns, particularly pancreatitis, is a major challenge for in vivo gene 
delivery.  
  A wide range of non-viral and viral gene delivery systems have been exploited to 
target the pancreas for therapeutic purposes and functional studies (225). Non-viral 
liposomes and nanoparticles have been commonly employed to deliver conjugated 
drugs/chemotherapy or therapeutic genes. However, a major limitation with non-viral 
delivery methods is low efficacy, and they require repeated delivery to achieve 
therapeutic benefit (226, 227). Viral vectors have been shown to be more efficacious to 
achieve long-term gene expression with limited off-target effects. Among the viral 
vectors, integrating lentiviral vectors target the pancreas efficiently (exocrine and 
endocrine) with no immune response (228). However, insertional mutagenesis is a major 
concern and limits its use for in vivo delivery (229, 230). By comparison recombinant 
adenovirus (rAd) or adeno-associated virus (rAAV) are predominately episomal, and 
both still achieve efficient in vivo pancreatic delivery (231, 232).  Ad vector mediated 
pancreatic gene transfer is transient in nature due to potent host immune responses and 
vector mediated cytotoxicity (233-235). On the other hand, non-integrating AAV vectors 
are particularly promising in efficiently targeting the whole pancreas (236-238).  Also 
both have the potential to target specific cell types in the pancreas (239-241) and 
pancreatic neoplasms(242), and both do not elicit humoral responses or alterations in 
physiological  pancreatic functions (236-238, 242, 243). AAV vectors contain a single-
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stranded (ss) DNA genome, with a packaging capacity of ~4.8 kb, and are able to mediate 
long-term transgene expression because of their lack of pathogenicity and low 
immunogenicity(244-246).  In addition, ssAAV vectors have been engineered to contain 
a double-stranded (ds) DNA genome (hairpin) to circumvent the requirement for second 
strand DNA synthesis, a requisite for transgene expression, and are self-complementary 
(sc) AAV viral vectors (247, 248). Improved scAAV vectors were shown to be more 
efficacious in in vivo gene delivery (249).  
Determining an ideal delivery route with limited off-target effects is another 
critical component to target the pancreas efficiently. A wide range of gene delivery 
routes have been exploited such as direct pancreatic injections (233, 238, 250), 
intraperitoneal (242, 251), systemic delivery (252, 253) and in conjunction with 
clamped hepatic circulation (236),  celiac/hepatic artery (254), and retrograde ductal 
delivery via pancreaticobiliary ductal infusion (224, 231, 237, 243), or catheterizing 
the cystic duct through the gallbladder/common bile duct (228, 236).  Among several 
AAV serotypes tested, AAV8 and AAV9 have been shown to be well-suited for 
systemic delivery (255, 256), and AAV6 has been shown to transduce the normal 
pancreas very efficiently via retrograde pancreatic ductal delivery (236). Accumulating 
evidence documents the use of AAV to deliver therapeutic molecules/genes to 
neoplasms, including pancreatic tumors (242, 257), and tissues undergoing rapid 
degeneration and regeneration (258, 259). However, a comprehensive study on ideal 
serotype, route, vector dose, and safety profile to target the pancreas with limited off-
target effects and in the context of cancer is not well established using scAAV vectors. 
In this study, we have investigated the use of three scAAV serotypes (AAV6, AAV8, 
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and AAV9) to target the pancreas via systemic delivery or retrograde targeted ductal 
delivery and optimized the vector dose to maximize pancreatic gene expression.  In 
addition, we evaluated the effect of ductal delivery mediated pressure on pancreatitis 
and use of AAV to target the pancreas in a PDAC mouse model driven by KrasG12D, a 
common Kras mutation found in PDAC.  We demonstrate that retrograde intraductal 
delivery of 5x1011 scAAV6.GFP vg/animal transduces the pancreas with >80% 
transduction efficiency, without causing fibrosis or inflammation. Furthermore, we 
have also shown that scAAV6 transduces acini, epithelial, and stromal cells in a PDAC 
mouse model with persistent long-term gene expression and does not adversely affect 
PDAC progression. 
 
4.2 Materials and Methods 
AAV vector production  
A self-complementary recombinant AAV vector encoding a green fluorescent 
protein expressing under ubiquitous EF1α promoter has been previously described (136). 
Recombinant AAV vectors were produced by a standard triple transfection calcium 
phosphate precipitation method using HEK293 cells (ATCC, CRL-1573). The production 
plasmids were: (i) scAAV.GFP (ii) rep2-cap6/8/9 modified AAV helper plasmid 
encoding the cap serotype 6, or 8 or 9, and (iii) an adenovirus type 5 helper plasmid 
(pAdhelper) expressing adenovirus E2A, E4, ORF6, and VA I/II RNA genes. Purification 
was accomplished from clarified HEK293 cell lysates by sequential iodixanol gradient 
purification and ion exchange column chromatography using a linear NaCl salt gradient 
for particle elution. Vector genome (vg) titers were determined by quantitative 
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polymerase chain reaction (qPCR) using EF1 primer and probe set as previously 
described (136, 260).  
AAV transduction efficiency  
Fresh tissues were harvested and fixed in 4% paraformaldehyde followed by 
overnight incubation in 30% sucrose and then embedded in OCT. Tissue blocks were cut 
into 6 µm sections using Leica cryostat. Transduction efficiency was determined by 
counting the number of GFP+ and negative acinar, ductal cells, PSCs, or islets using four 
random 20x GFP and DAPI overlay images. To further quantify transduction efficiently, 
GFP transgene qPCR was performed on total DNA isolated from pancreatic and liver 
tissues. Total tissue DNA was isolated using the Gentra Puregene kit (Qiagen) according 
to the manufacturer’s instructions. 60 ng of DNA (10,000 cell equivalents) was used as 
PCR template in triplicate reactions and vg numbers were extrapolated from a linearized 
plasmid standard. Vector genome/cell calculations assume 6 pg of total DNA per cell 
using GFP primer and probe set as previously described (136). 
Whole organ pancreatic GFP expression  
At necropsy, the abdominal cavity was opened, and the whole pancreas was 
imaged for GFP expression using a LEICA dissecting fluorescent microscope.  
H&E, Masson’s trichrome/Sirius Red staining  
After formalin fixation, specimens were dehydrated through a graded series of 
ethanols, cleared in two changes of xylenes and infiltrated through 3 changes of melted 
paraffin.  The specimens are then embedded in melted paraffin and allowed to 
harden.  Thin sections (~5 µm) were cut using a rotary microtome equipped with 
disposable steel knives.  Sections were flattened on a heated water bath, floated onto 
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microscope slides and dried.  Serial sections were de-paraffinized and stained for 
Hematoxylin and Eosin (H&E), Masson’s trichrome staining (Sigma-Aldrich, HT15-
1KT) and Picro-Sirius Red to detect pancreatic fibrosis following standard histological 
procedures or as per the manufactures instructions. Similarly, serial frozen sections (~5-
7µm) were stained for H&E. 
B220-immunohistochemistry  
Antigen retrieval was performed at high pH in the Dako Link PT module. After 
treating with a protein block (Dako) for 10 min, slides were incubated with CD45 
primary antibody (clone B220BD Pharmingen, BD-550286, 1:50) for 60 min followed by 
biotinylated-anti-rat IgG (Jackson Immuno-Research) for 30 min, and finally with 
LSAB2-SA-HRP (Dako) for 30 min. The chromogen was developed with DAB (Dako). 
All steps were separated by tris buffer (Dako) washes and performed at room 
temperature. All histological stains were performed by histology cores at IU School of 
Medicine.  
PanIN analysis in KC mice  
Using a standard H&E slide, small clusters of abnormal ducts were looked at as a 
first target. Using the Johns Hopkins School of Medicine classification system (261), 
clusters of abnormal ducts were classified into PanIN grades 0 (normal), 1-A, 1-B, 2, and 
3. Each duct in the cluster was scored and PanIN size analysis was done using the Aperio 
Imagescope system.  
Fibrosis and immune response quantification  
The slides were analyzed using Aperio Imagescope and the FDA approved 
algorithm with few a modifications. The entire pancreatic tissue was analyzed, with the 
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exclusion of vessels, lymph nodes, and peri-pancreatic fat. Trichrome: FDA approved 
algorithm was altered to detect blue against a red background. Hue value was altered 
from 0.1 (Brown) to 0.62 (Blue), hue width was altered from 0.5 to 0.4, and color 
saturation was altered from 0.04 to 0.005. Sirius Red:  Hue value was altered from 0.1 
(Brown) to 0.85 (Red) and hue width was not changed. Color saturation was altered from 
0.04 to 0.6. The intensity threshold was lowered from 175 to 100. B220: A pathologist 
reviewed the slides and determined the quantity of cells that were B220 positive.  
Immunostaining  
Serial frozen sections (5-7 µm) were rehydrated in PBS, permeabilized with 0.5% 
Triton X solution, blocked with 10% BSA, and probed with either α-SMA antibody 
(Novus Biologic, NB500-631, 1:200), CK19 antibody (Abcam, ab52625, 1:200), insulin 
antibody (Cell Signaling, 4590S, 1:200), or α-Amylase (Cell Signaling, 3796S, 1:200) 
overnight at 4oC. Epitope retrieval was performed using 1x sodium citrate buffer 
followed by Triton X permeabilization. Subsequently, slides were stained with secondary 
antibody Alexa Fluor 594 goat anti-rabbit IgG (Life Technologies, A11037, 1:1000). 
Slides were mounted with Vectashield antifade mounting medium with DAPI (Vector 
Laboratories, H-1200) and coverslips were sealed.  
GFP Immunohistochemistry  
Paraffin embedded tissues were sectioned (5 µm) and epitope retrieval was 
performed using heat-induced epitope retrieval (HIER) with 10 mM citrate buffer. 
Endogenous peroxidase activity was blocked using 3% H2O2 in methanol and 
subsequently blocked with 0.5% BSA. Primary antibody, mouse anti-GFP (Cell 
Signaling, #2955, 1:200), was applied and incubated overnight at 4oC. Secondary anti-
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mouse IgG was utilized from Vectastain mouse IgG ABC kit (Vector Labs, PK-6102) 
and developed with peroxidase substrate solution consisted of 0.05% DAB and 0.01% 
H2O2 in PBS via the manufacturer’s protocol. Sections were counterstained in Gill No. 1 
hematoxylin (Leica Biosystems, 3801520), cleared, and mounted with a resin-based 
mounting medium. 
Retrograde Pancreatic Ductal Delivery 
Mice were sedated using isoflurane with 1.5-3% oxygen, the abdominal cavity 
was opened, and a customized catheter was inserted into the cystic duct through a small 
opening at the bottom of the gallbladder. The catheter was then advanced into the 
common bile duct and secured in place with a micro clamp around the bile duct and 
catheter to prevent vector reflux into the liver. A micro clamp was placed on the sphincter 
of Oddi to avoid leakage of the vector into the duodenum, and 100µl of AAV vector 
containing the GFP transgene or PBS (vehicle control) was slowly infused into the 
pancreatic duct through the catheter. Successful administration was documented by 
uniform swelling of the gland. The micro clamps used to temporarily block liver infusion 
and duodenum leakage were released 5 min after the infusion was completed. The 
catheter was then removed, the inner abdominal cavity was closed with absorbable 
sutures, and the outer skin was closed with wound clips. Post-surgery, mice were placed 
on a heating pad to maintain body temperature during recovery. Once the animals 
recovered, they were returned to their cages. Mice were treated subcutaneously with 
Carprofen (5-10mg/kg) to prevent post-operative discomfort.  
Mice 
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KC mice were generated as described (113). Conditional LSL-KrasG12D mice were 
crossed with Pdx1-Cre animals to generate the KC mice. All animal housing, use, and 
surgical procedures were carried out in accordance with the regulatory guidelines set by 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. 
All animal protocols were reviewed and approved by the Indiana University (IU) and The 
Research Institute at Nationwide Children’s Hospital Animal Care and Use Committees. 
Statistical analysis 
Student’s t-test and Analysis of Variance with Tukey post-hoc analysis was used 
for statistical analysis. Data is presented as mean and error bars are represented as 
standard error of the mean. 
 
4.3 Results  
Comparison of scAAV8 and scAAV9 serotypes to target the pancreas via systemic 
delivery 
In both clinical and pre-clinical settings, either direct injection or systemic 
delivery to the target tissue are preferred routes of administration for therapeutic 
purposes because of their ease of use. As direct injection of the pancreas would be 
more invasive and may not achieve uniform gene expression in the entire pancreas, for 
our initial studies, we elected systemic delivery. Previously, systemic delivery of 
ssAAV serotype 8 and 9 (AAV8 and AAV9) has been demonstrated to modestly 
transduce the pancreas (255, 256). scAAV vectors are known to transduce target 
tissues with higher efficiency compared to ssAAV vectors (249). To test the ideal 
serotype for systemic delivery, scAAV viral vector expressing green fluorescent 
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protein (GFP) under EF1α promoter (scAAV.GFP) (Figure 49A) was packaged using 
AAV8 and AAV9 serotypes, and 1x1012 vg/animal were delivered systemically (n=3 
mice/group) to normal C57BL/6 mice, and animals were sacrificed at 3 weeks post-
vector administration. As documented by fluorescence microscopy for GFP expression, 
AAV9 showed modestly higher pancreatic transduction efficiency (14.6% ± 2.5 
Standard Error of the Mean - S.E.M.) compared to AAV8 (11.5 % ± 0.2 S.E.M.) 
(Figure 49B) with some off targets (Figure 50). 
 To test the ideal dose for achieving maximum pancreatic transduction efficiency 
via systemic delivery of scAAV9.GFP, we compared three different doses ranging from 
1x1012-5x1012 vg/animal. Although increase in vector dose improved transduction 
percentages, none of the tested doses reached >45% pancreatic transduction efficiency 
(Figure 49C, Figure 49D). This level of gene expression may be sufficient to develop 
therapeutic strategies for non-neoplastic tissues, but in the context of cancer, optimal 
transduction efficiency is preferred for therapeutic benefit and functional studies. Further 
dose increase via systemic delivery may improve transduction efficiency, but producing 
large quantities of clinical vectors for dosing adult PDAC patients without causing 
toxicity with high dose may be challenging.  
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Figure 49. Comparison of scAAV8 and AAV9 to Target the Pancreas via Systemic 
Delivery. (A) Schematic of the scAAV.GFP vector. (B) Quantification of GFP 
expression in C57BL/6 mice administered 1 x 1012 vg/animal of scAAV8.GFP and 
scAAV9.GFP via tail vein injection (n = 3/group), as determined by percentage GFP+ 
acinar cells. A representative image of global pancreatic GFP expression is shown below 
each graph column; 6 mm frozen tissue sections. (C) Quantification of GFP expression in 
C57BL/6 mice administered scAAV9.GFP at various doses via tail vein injection (n = 
3/group), as determined by percentage GFP+ acinar cells. (D) Representative global 
pancreatic GFP expression of C57BL/6 mice dosed with 5 x 1012 vg scAAV9.GFP 3 
weeks post-vector administration. 20X magnification. Data represent mean ± SEM; *p < 
0.05. 
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Figure 50. Assessment of off-target effects for AAV9 systemic delivery and AAV6 
retrograde pancreatic intraductal delivery. Multiple organs were harvested from mice 
that were systemically dosed with scAAV9.GFP at 5x1012 vg/animal and (A) global 
representative image of liver GFP expression via florescence microscopy is presented, as 
well as (B) heart, lung, and kidney, with H&E stained serial sections (20X magnification, 
scale bar 50 µm). (C) Heart, lung, and kidney of mice intraductally dosed with 
scAAV6.GFP at 5x1011 vg/animal were harvested and serial sections were taken to assess 
global GFP expression determined via florescence microscopy and H&E staining for 
heart, lung, and kidney (20X magnification, scale bar 50 µm). 
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Retrograde intraductal infusion of scAAV6 transduces the pancreas uniformly and 
efficiently.  
A wide range of gene delivery methods were previously evaluated to directly 
target the pancreas such as retrograde pancreatic ductal delivery by direct injection of the 
distal common bile duct (224, 237), cannulation of the common bile duct through the 
gallbladder/cystic duct, and intravenous injection coupled with liver blockage (236). 
Although each of these methods were shown to be effective to transduce the whole 
pancreas or various cell types of the pancreas (acini, islet of Langerhans, and ductal 
cells), we elected retrograde ductal delivery via cannulation of the common bile duct to 
evaluate its safety profile and use in cancer settings using scAAV vectors.  
Initially to optimize the conditions for cannulation and retrograde ductal delivery, 
we dosed a cohort of mice with Evans Blue dye. As elaborated in the methods section, a 
customized 10 mm catheter was advanced through the gallbladder and cystic duct to the 
common bile duct (Figure 51A). A micro clamp is placed on the bile duct and sphincter 
of Oddi to prevent vector leakage into the liver and small intestine, and 100 µl of Evans 
Blue was injected over 2-3 minutes to target the pancreas. We observed a uniform 
distribution of Evans Blue in the entire pancreas (Figure 51A). 
 Subsequently, to test the efficacy of rAAV to target the pancreas, in our initial 
studies, we packaged scAAV.GFP with the AAV6 serotype, which has been shown to 
efficiently target the pancreas (236, 237).  We administered 1x1011 vg/animal of 
scAAV6.GFP via retrograde ductal delivery, and animals were sacrificed three weeks 
later for global pancreatic GFP expression analysis. As documented under direct 
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fluorescence, scAAV6 transduced the pancreas with uniform GFP expression (Figure 
51B). 
   
Identification of an AAV serotype to efficiently target the pancreas via retrograde 
intraductal infusion. 
Single-stranded AAV 6, 8, and 9 serotype vectors have been shown to transduce 
the pancreas efficiently via retrograde pancreatic intraductal delivery (262). However, the 
efficiency of scAAV vectors has not yet been determined. To address this question, we 
compared scAAV.GFP serotypes 6, 8, and 9, and dosed a cohort of C57BL/6 mice for 
each serotype (n=3-4 mice/group) with 1x1011 vg/animal via retrograde pancreatic ductal 
delivery. At 3 weeks post-vector infusion, animals were sacrificed, and pancreata were 
collected from each animal to compare GFP transduction efficiency. As documented by 
fluorescent microscopy, scAAV6 and scAAV9 transduced acinar cells (exocrine cells) 
more efficiently with 53% ± 3.8 S.E.M. and 52% ± 2.7 S.E.M., respectively (Figure 51C) 
compared to scAAV8 (21.7% ± 5.9 S.E.M.). Similarly, scAAV6 transduced ductal cells 
(48.2% ± 10.25 S.E.M.) more efficiently compared to scAAV8 (12.1% ± 3.2 S.E.M.) and 
scAAV9 (13.6% ± 3.7 S.E.M.) (Figure 51D). Furthermore, scAAV6 transduced 
pancreatic islet cells with relatively higher efficiency (82.1% ± 3.1 S.E.M.) compared to 
scAAV8 (16.3% ± 3.1 S.E.M) and scAAV9 (30.5% ± 5.0 S.E.M) (Figure 51E). To 
achieve maximum pancreatic transduction via intraductal delivery, we dosed a cohort of 
mice (n=3-5 mice/group), with three escalating doses (1x1011, 3x1011, and 5x1011 
vg/animal) using scAAV6.GFP. Quantification of the transduced exocrine acinar cells 
 135 
showed an increase in transduction percentages and with maximum gene expression 
achieved at 5x1011 vg (Figure 51F).   
As scAAV6 and scAAV9 showed comparable transduction efficiency at the 
lowest dose (1011 vg/animal), to determine maximum pancreatic gene expression in this 
model, we compared the transduction efficiency of AAV6 and AAV9 at a dose of 5x1011 
vg/animal. AAV6 had statistically significant higher pancreatic GFP expression (86% ± 
2.4 S.E.M.) compared to AAV9 (75% ±1 S.E.M.) (Figure 52A, Figure 52B).  We also 
examined GFP expression in the livers of these mice (a common off-target of 
intraductally dosed mice (243, 262)), and AAV9 has relatively higher liver transduction 
percentages compared to AAV6 (Figure 52A). To further confirm this observation, we 
quantified transduced vector genomes of the pancreas and liver by quantitative real-time 
PCR (qPCR). AAV6 had more specificity in targeting the pancreas with more vector 
genomes compared to AAV9. Whereas AAV9 had relatively very high vector genome 
copies in the liver compared to AAV6 (Figure 52C). We further tested this phenomenon 
in animals dosed with 5x1011 vg/animal of AAV6 and AAV9 and found that AAV6 has 
more specificity in transducing the pancreas compared to AAV9 (Table 3). scAAV6 
mediated GFP expression was not found in any other tissues in the body including heart, 
lung, and kidney (Figure 50C). Finally, to test the effect of murine gender on AAV6 
mediated pancreatic transduction, we dosed a cohort of C57BL/6 males and females with 
5x1011 vg of scAAV6.GFP (n=3 mice/group) and found that the gender did not have a 
significant effect on pancreatic transduction (Figure 52D).  
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Figure 51. Optimization of Retrograde Intraductal Infusion via Catheterizing the 
Common Bile Duct through the Gallbladder and Cystic Duct. (A) Uniform Evans 
Blue dye delivery to the entire pancreas via the retrograde intraductal infusion procedure. 
(B) A C57BL/6 mouse was dosed with 1 x 1011 vg of scAAV6.GFP via retrograde 
intraductal infusion, and pancreatic GFP expression was observed via direct fluorescence. 
(C–E) A cohort of C57BL/6 mice was dosed with scAAV6.GFP, 8, or 9 at 1 x 1011 
vg/animal (n = 3–4/group). Serial sections of frozen (6 mm) pancreatic tissue collected 3 
weeks post-vector infusion were stained for (C) amylase (AMY2, acinar cells), (D) 
Cytokeratin 19 (CK19, ductal cells), or (E) insulin (INS, islets) or with H&E to quantify 
cell-specific GFP transduction percentages. GFP, green; AMY2, CK19, or INS, red; 
DAPI, blue; 20X magnification; scale bar, 50 mm; representative images are presented. 
(F) A cohort of C57BL/6 mice was intraductally infused with different doses of 
scAAV6.GFP (n = 4–6/group), and the percentage of GFP+ acinar cells was determined. 
Data represent mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 52. scAAV6 Has Increased Specificity in Transducing the Pancreas 
Compared with scAAV9 C57BL/6 mice were dosed with scAAV6.GFP or 
scAAV9.GFP at 5 x 1011 vg/animal. (A) Pancreatic and liver GFP+ expression was 
determined via fluorescence microscopy. Representative pancreatic and liver images are 
shown for each serotype at 20 magnification. (B) Quantification of pancreatic and liver 
transduction was determined by the percentage of GFP+ acinar cells and hepatocytes, 
respectively. (C) DNA was isolated from pancreata and livers of scAAV6.GFP or 
scAAV9.GFP retrograde intraductally infused C57BL/6 mice and subjected to qPCR 
analysis for AAV genome copy numbers. Data represent mean ± SEM. *p < 0.05. (D) 
Quantification of pancreatic GFP expression was determined in male and female 
C57BL/6 mice dosed with 5 x 1011 vg of scAAV6.GFP. 
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Table 3. Comparison of scAAV6 and scAAV9 pancreatic transduction efficiency via 
retrograde intraductal delivery (vector genomes/nuclei) C57BL/6 mice were dosed 
with scAAV6.GFP or scAAV9.GFP at 5x1011 vector genomes (vg)/ animal and vg per 
cell was determined by qPCR. 
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AAV6 targets and shows long-term gene expression in acinar, epithelial, and stromal 
cells in PDAC mice.  
To test the feasibility of using scAAV6 to target the pancreas of PDAC mice, we 
dosed a cohort of a well-characterized PDAC mouse model, KC, with scAAV6.GFP at 1 
month of age via intraductal delivery. As documented via fluorescence microscopy and 
immunohistochemistry for GFP, scAAV6 transduced KC mice pancreata efficiently at 3 
weeks post-vector administration (Figure 53). To test AAV mediated long-term gene 
expression, we collected the pancreata of scAAV6.GFP intraductally dosed KC mice at 5 
months post-infusion and found persistent GFP expression (Figure 54, Table 2) in acinar, 
epithelial/cancer, islet, and pancreatic stellate cells (PSCs).  scAAV6 transduced PSCs 
(28.5% ± 4.7 S.E.M.) and PanIN)/ducts (7.6% ± 2.6 S.E.M.) with relatively lower 
efficiency compared to acinar cells (55.0% ± 16.5 S.E.M.) and islets cells (41.5% ± 5.5 
S.E.M.) (Figure 54, Table 4).  The efficiency of scAAV6 to target neoplastic tissues 
needs to be further optimized through understanding mechanisms associated with AAV6 
transduction in the various pancreatic compartments. Nevertheless, our findings provide 
the evidence that persistent gene expression can be achieved in proliferating epithelial 
and stromal cells in the context of a genetically engineered mouse model of pancreatic 
cancer. 
 
 
 
 
 141 
 
Figure 53. Retrograde pancreatic intraductal delivery of scAAV6 targets KC mice 
pancreata at early timepoint (3 weeks post-injection). KC mice were intraductally 
infused with 5x1011vg of scAAV6.GFP and pancreata was collected at 3 weeks post-
vector administration for early timepoint and were either (A) stained with α-SMA (red) 
and DAPI (blue) to assess GFP expression via fluorescent microscopy (60X inset) or (B) 
subjected to immunohistochemistry (IHC) for GFP expression and hematoxylin and eosin 
(H&E) staining (20X). Acinar cells (Ac), pancreatic ducts (D), and stromal compartments 
(S) are indicated. 
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Figure 54. Retrograde Pancreatic Intraductal Delivery of scAAV6 Targets Acinar, 
Epithelial, and Stromal Cells and Shows Long-Term Gene Expression in PDAC 
Mice. 5 x 1011vg of scAAV6.GFP was dosed in 1-month-old KC mice, and pancreata 
were collected 5 months post-delivery for the late time point and stained for amylase 
(AMY2), CK19, α-SMA, or insulin (INS) to identify acinar cells, ductal cells, PSCs, and 
islet cells, respectively. Serial sections were stained with H&E, and representative images 
are presented. GFP, green; AMY2, CK19, α-SMA, or INS, red; DAPI, blue; 20 
magnification; scale bars, 50 mm; inset, 40; arrows indicate α-SMA+/GFP+ PSCs. 
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KC Compartment %Transduction 
Acini (AMY2) 55.0% ± 17 S.E.M. 
Epithelial Cells (CK19) 7.6% ± 2.6 S.E.M. 
PSCs (α-SMA) 28.5% ± 4.7 S.E.M. 
Islets (INS) 41.5% ± 5.5 S.E.M. 
 
Table 4. Percentage Longterm GFP expression Retrograde Pancreatic Intraductal 
Delivery of scAAV6 
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Retrograde intraductal delivery is safe with no evidence of pancreatitis in normal 
pancreata nor enhanced disease progression in PDAC mice.  
Increase in pancreatic intraductal pressure is known to cause 
inflammation/pancreatitis, a known risk factor for PDAC (263-265). To evaluate the 
effect of intraductal delivery mediated pressure on pancreatic inflammation, we dosed a 
cohort of C57BL/6 mice with PBS and monitored serum pancreatitis markers, amylase 
and lipase (266-268). We observed a rapid increase in amylase and lipase levels at 3 
hours post-vector delivery which resolved within a day of intraductal infusion (Figure 
55A, Figure 55B). By histopathological examination, there was minimal to no pancreatic 
inflammation seen at various timepoints (Figure 55C), except for a detectable peri-
pancreatic fat lymphoid response in a few mice at 2-5 days post-infusion (Figure 55D). 
We also stained pancreata with the B cell marker (B220) to monitor lymphoid responses. 
Normal mice were negative for B220 at all timepoints, 1-15 days post-infusion (Figure 
55C; Table 5). In addition, to evaluate the effect of intraductal mediated pressure on 
pancreatic fibrosis, we stained pancreata of C57BL/6 mice with trichrome (Figure 55C) 
and found no significant increase in pancreatic fibrosis in intraductally dosed mice 
compared to non-injected control mice (Figure 55E).  
Finally, to evaluate the effect of intraductal delivery mediated inflammation on 
PDAC progression, we performed histopathological analysis in KC mice dosed with PBS 
or scAAV6.GFP at 5 months post-infusion. As shown in Figures 56A-C, there was no 
significant difference in the size and number of PanIN grades between intraductally 
infused KC mice and controls. Furthermore, intraductually infused KC mice were 
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negative for B220 staining <1% (Table 6), and there was no significant increase in 
pancreatic fibrosis based on trichrome staining (Figure 56C).  
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Figure 55. Retrograde Pancreatic Intraductal Delivery Is Safe and Does Not Induce Chronic Pancreatitis. (A and B) Serum 
samples collected from intraductally dosed (100 mL PBS) C57BL/6 mice were analyzed for (A) amylase and (B) lipase. Data 
represent mean ± SEM; *p < 0.05; **p < 0.01; n.s., non-significant. (C) Representative H&E, trichrome, and B220 images; 20 
magnification; scale bars, 200 mm. (D) Representative fat lymphoid responses observed at early time points (1–3 days, H&E). Scale 
bars, 200 mm, 20 magnification. (E) Mean Sirius Red- or trichrome-positive area (percent) of pancreatic tissue in retrograde 
pancreatic intraductally injected C57BL/6 (1–14 days post-infusion) mice (n = 3–4 mice/time point). Data represent mean ± SEM.
 147 
 
Table 5. Histological analysis of B cell activation (B220) in retrograde pancreatic 
intraductally infused KC mice. Pancreata collected from intraductally dosed (100µl 
PBS or scAAV6.GFP) KC mice at 5 months post-infusion were analyzed for B220 
staining. Histological descriptions by a pathologist are provided for individual animals. 
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Figure 56. Retrograde Pancreatic Intraductal Delivery has No Effect on PDAC 
Progression in KC mice. Pancreata collected from KC mice at 5-months post-infusion 
(100 µl of PBS or 5x1011vg scAAV6.GFP) was analyzed and compared against un-
injected control mice for (A) PanIN grades (1A/B, 2, & 3) (n=3-5 mice/group) and 
representative images for each PanIN grade are shown indicated by black arrows. 
Adjacent PanIN-3 lesion is indicated by red arrows. 20X magnification, Scale bar 100µm, 
(B) Average area of PanIN lesions and (C) number of PanIN lesions per mouse are 
presented (n=5-7 mice/group). (D) Trichrome staining positive percentage area was 
quantified (n=3-5 mice/group). Data represents mean ± S.E.M. p-values determined by t-
test, n.s.: non-significant. 
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4.4 Discussion 
Previously, numerous non-viral and viral mediated delivery methods were 
employed to deliver therapeutic molecules/genes to the pancreas via direct (233, 238), 
systemic (253, 254), intraperitoneal (242), and retrograde ductal delivery (224, 228, 236). 
Among various vector systems and routes of administration, retrograde ductal delivery of 
AAV demonstrated efficient pancreatic gene expression (236, 237, 243). However, the 
safety and efficacy of retrograde ductal delivery on the development of pancreatitis, a 
known risk factor for PDAC, and use of AAV in cancer settings has not been well 
established. Here in the current study, we compared the use of different AAV serotypes 
for efficient delivery to the pancreas via intravenous (AAV8 and AAV9) or retrograde 
pancreatic ductal delivery (AAV6, AAV8, and AAV9) using double-stranded scAAV 
vectors expressing GFP under a ubiquitous promoter, EF1α. Our results indicate that 
retrograde pancreatic ductal delivery of scAAV6 via catheterizing the common bile duct 
through the gall bladder/cystic duct transduces various cell types of the pancreas, such as 
acini, ducts, and islets, efficiently compared to scAAV8 and scAAV9 without inducing 
pancreatitis. Furthermore, as a proof-of-concept, we showed that retrograde pancreatic 
ductal delivery of scAAV6 transduces acini, epithelial, and stromal cells in a pre-clinical 
PDAC mouse model and demonstrated persistent gene expression up to 5 months post-
infusion. 
Although direct pancreatic targeted delivery is very robust and achieves 
maximum gene expression, because of retroperitoneal location of the pancreas, a less 
invasive systemic gene delivery is a preferred method of choice in clinical settings. In 
an attempt to identify a serotype that can be used to efficiently target the pancreas via 
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systemic delivery, we compared pancreatic transduction efficiency of scAAV8 and 
scAAV9.  scAAV9 showed relatively higher pancreatic transduction efficiency 
compared scAAV8 via systemic gene delivery. However, maximum acinar gene 
expression was <60% in spite of high scAAV9 dose, 5x1012 vg/animal.  Previous 
reports indicate that systemic delivery of ssAAV9 transduces pancreas robustly at a 
relatively low vector dose (1.8x1012 vg/animal) (256).  Perhaps, the lower transduction 
percentage observed in gene expression could be due to the use of an endogenous 
promoter, EF1α, compared to the CMV promoter used in previous studies (256). We 
used scAAV9 compared to the ssAAV9, which are known to transduce more 
efficiently compared to ssAAV(249). In spite of utilizing scAAV vectors, pancreatic 
transduction efficiency via systemic delivery was significantly lower compared to 
previous reports that used ssAAV vectors. Perhaps the low pancreatic transduction 
percentage via systemic delivery may fulfill the required gene expression levels for 
studies involving pancreatic origin diseases such as diabetes, where restoration of a 
few functional copies of a gene may have a functional/therapeutic effect. 
       Similar to previous reports using ssAAV (236, 237, 243), our observations 
demonstrate that efficient pancreatic transduction can be achieved via retrograde 
pancreatic ductal delivery of scAAV, a surgical procedure that parallels the clinical 
endoscopic retrograde cholangiopancreatography (ERCP) in humans.  Among the three 
AAV serotypes tested via pancreatic ductal delivery, AAV6 transduced the whole 
pancreas and various pancreatic compartments (acini, ducts, islets) more efficiently 
compared to AAV8 and AAV9.  Transduction efficiency of intraductal mediated delivery 
of AAV6 via EF1α promoter in various pancreatic compartments is comparable to 
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previous reports using CMV promoter (237). In addition, AAV6 has relatively minimal 
liver transduction, a common off-target of intraductally dosed mice (236, 243). AAV9 
had comparable pancreatic targeting efficiency to AAV6, but showed higher liver 
transduction. The increase in liver transduction with AAV9 may be due to the higher 
abundance of receptors and/or co-receptors to AAV9 in hepatocytes or increased 
circulation residence and is consistent with a previous report indicating that AAV9 
transduces the liver more efficiently upon systemic injections compared to AAV6 (256).  
As the liver is a common site for metastasis in pancreatic cancer, AAV9 may be more 
appealing for gene delivery at later disease stages in a metastatic context.  
 Our results also demonstrate that retrograde pancreatic ductal delivery is safe and 
does not induce pancreatitis in mice.  Although we observed transient increase in 
pancreatitis markers at ~1 day post-infusion, amylase and lipase levels resolved within 24 
hours. Furthermore, no significant increase of lymphoid proliferation or fibrosis was 
observed by histopathological examination in intraductally infused mice. Pancreatitis is a 
known risk factor for PDAC, and patients with chronic or acute pancreatitis have a higher 
risk of developing cancer and can experience enhanced cancer progression. To test the 
safety of intraductal mediated delivery in cancer settings, we evaluated the PanIN 
progression in a well characterized PDAC mouse model dosed with PBS and 
scAAV6.GFP and found no effect on cancer progression.  
 Finally, to test the potential use of scAAV to target the pancreatic neoplasm via 
retrograde delivery, we dosed 1 month old KC mice, a KrasG12D driven PDAC mouse 
model, with scAAV6.GFP and found efficient transduction in acinar and ductal cells 
(primary cells of origin for PDAC) and PSCs, the major cells responsible for PDAC 
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stromal accumulation(38, 85). Furthermore, we observed long-term GFP expression in 
amylase+ acini, CK19+ ductal, and α-SMA+ stromal cells at 6 months of age, a timepoint 
at which KC mice develop more advanced PanIN2-3 lesions (113). In addition to our 
work, a recent report demonstrated the use of capsid optimized scAAV8 to target 
pancreatic neoplasm via intraperitoneal administration (242). Although capsid optimized 
AAV8 has limited off-target effects compared to WT AAV8, there was a robust gene 
expression in the liver comparable to the pancreas which could be improved in 
combination with the retrograde pancreatic targeted delivery we employed here to 
efficiently target the pancreas.  
 Our current research and recent reports from others (242) indicate the potential 
applicability of AAV to deliver therapeutic molecules/genes to various compartments of 
PDAC and impact tumor progression. Similarly, previous reports indicate that ductal 
delivery of AAV in combination with cell specific promoters serves as an excellent 
surrogate for pancreatic cell lineage studies (239-241). Another potential application of 
this work is using AAV as a non-integrating delivery vehicle for genome editing 
mediated functional studies. The latest developments in genome sequencing technologies 
are rapidly unravelling new genes underlying various human diseases (269). However, 
alternative and more rapid methods to transgenic mouse models are required for in vivo 
characterization of new genes in order to quickly translate basic research findings into the 
clinic (223).  
Genome editing tools such as CRISPR/Cas9 have become useful to study gene 
function (270-272). In fact, surrogate use of retrograde pancreatic targeted delivery of 
Cre-recombinase or CRISPR/Cas9 via integrating adeno and lentiviral vectors has been 
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elegantly demonstrated to lead to the development of PDAC mouse models (224). AAV 
mediated pancreatic targeted delivery described here in combination with cell specific 
promoters is amenable to genome editing technologies to study in vivo gene function and 
will aid in accelerating basic research findings into the clinic. The AAV platform is more 
attractive as its safety profile and ideal serotypes are well established to target various 
tissues. Although viral vectors may not replace mouse models, they will serve as great 
tools to further advance pre-clinical research by studying the gene function alone or in 
combination with known genetic causes. The retrograde ductal delivery will be a useful 
tool in studying the gene function of non-coding RNAs, such as miRNAs. Often a single 
miRNA has several family members (92, 273, 274) that are expressed in a tissue and cell 
specific manner. Developing a tissue/cell specific mouse models for individual miRNA 
family members in combination with underlying disease related genetic mutations is a 
daunting process. Using a similar method described here, miRNA families can be 
inhibited by developing AAV vectors for miRNA inhibition strategies such as Tough 
Decoys (TuDs), anatagomirs, etc. Proof-of-concept studies suggest the use of viral 
vectors to inhibit endogenous miRNAs (275-277). Similarly, delivering synthetic miRNA 
duplexes, for therapeutic purposes has potential limitations associated with half-life and 
requires repeated administration (278). Evidence suggests the use of AAV for in vivo 
delivery of therapeutic miRNA with no toxicity (136, 279).  
In summary, our study demonstrates that scAAV6 targets both normal and 
neoplastic pancreas via retrograde ductal delivery. Our previous work and that of 
others supports the use of AAV vectors to target a wide variety of neoplasms (136, 
155, 257, 280-283) and target tissues undergoing multiple cycles of degeneration-
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regeneration (284-286). However, a number of pre-clinical studies need to be 
performed before this method reaches clinical settings due to the fact that AAV is a 
non-integrating vector and its expression is lost in rapidly proliferating neoplastic 
tissue.  First, transduction efficacy in KC mice needs to be evaluated in animals dosed 
at early stages of PanIN-1A/B development at <2 months of age versus more advanced 
stages of PanIN-2-3 lesions at ~9 months of age (113). Second, transduction efficiency 
and long-term gene expression need to be evaluated in a more aggressive PDAC mouse 
model that recapitulate the aggressive form of human disease such as KrasG12D; 
P53R172H; PDX1-Cre, etc (215). Third, further refinements to the gene transfer vector 
will be necessary to allow for cell-specific targeting of pancreatic tumors, similar to 
previous reports (239-241). Fourth, the underlying mechanisms for efficient scAAV6 
pancreatic transduction in neoplastic tissues and AAV receptor profiling in various 
pancreatic compartments and cancer cells needs to be evaluated, particularly in order to 
further optimize transduction efficiency of neoplastic tissue.  Fifth, the present study 
also points out the limitations of AAV to achieve high levels of long-term gene 
expression in rapidly dividing neoplastic tissue. Nevertheless, our results point out the 
potential use of AAV in early stages of cancer development, where transient 
therapeutic gene expression may have an impact on the disease progression and could 
be used to treat patients with pancreatitis, PDAC patients prophylactically, or as an 
adjunct therapy. Furthermore, targeted AAV mediated in vivo gene delivery to various 
pancreatic compartments will serve as a great tool in pre-clinical functional studies. 
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Chapter 5: Summary and Future Directions 
 Our work provides proof-of-concept evidence for the use of miR-29 as an 
anti-fibrotic and tumor suppressor agent in PDAC. However, several open-ended 
questions still remain. 
 
5.1 The Role of miR-29 in PDAC Stroma 
Our findings show that miR-29 plays a critical role in regulating tumor stromal 
deposition and cancer growth. Thus, raising the possibility that modulation of miR-29 
expression in PSCs may be therapeutically beneficial in cancer. Nevertheless, some groups 
have reported pancreatic stroma acts to restrain tumor growth, not promote it (35, 36). A 
subtler approach of converting activated PSCs to quiescence led to a more promising 
therapeutic outcome, in contrast to complete stromal ablation (37). Consistent with this 
more nuanced tactic, we would expect that miR-29 restoration in PSCs would result in 
hampered ECM production but not the complete depletion of existing stromal proteins. 
Furthermore, our findings demonstrate that miR-29 overexpression in PSCs leads to 
decreased cancer growth in co-culture without affecting the intrinsic viability of PSCs 
themselves. However, the effect of miR-29 on PSC activation has not been assessed. In 
addition to increased α-SMA expression, the loss of retinol lipid droplets is a critical 
hallmark of activated PSCs (287). A simple experiment of assessing α-SMA expression 
and Vitamin A droplets within miR-29 overexpressing PSCs could determine if miR-29 
reverts activated PSCs to quiescent ones, similar to calcipotriol treatment. If this holds true, 
miR-29 could also serve as a more tactical way to normalize the reactive stroma and 
enhance the efficacy of chemotherapy to target PDAC.  
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5.2 The Role of miR-29 in PDAC Autophagy 
miR-29 has been shown to play a significant role in regulating autophagy. Initial 
studies in bovine cells infected with virus revealed endogenous bovine miR-29 had an 
anti-viral, protective effect within the host cell by upregulating miR-29b, leading to the 
targeting of ATG14 and ATG9A. As bovine diarrhea virus (BVDV) utilizes host cell 
autophagy machinery as a means of promoting viral replication, miR-29b mediated 
inhibition of autophagy led to a decrease in BVDV replication (288).  
We have shown that miR-29a has a similar effect in inhibiting pancreatic cancer 
cell autophagy. This is of interest as previous reports demonstrated that pancreatic cancer 
cells heavily upregulate autophagy for survival and autophagy facilitates chemoresistance 
against gemcitabine (39). Similarly, we found that miR-29a overexpression led to 
increased gemcitabine sensitization in chemoresistant cell lines along with a concurrent 
late stage blockage of autophagy mediated through TFEB and ATG9A downregulation.  
Interestingly, miR-29b overexpression has also been shown to cause a decrease in 
TFEB expression in multiple myeloma (289). Although the authors postulated that this 
was an indirect effect of miR-29 mediated repression of HDAC4, it may be possible they 
were observing a direct targeting of TFEB by miR-29b as well. In contrast to our 
findings, the earlier study went on to show that miR-29b in myeloma cells had no impact 
on autophagy flux (289). These results indicate that miR-29 inhibition of autophagy may 
be context dependent or differ between miR-29a and -29b family members. Further 
investigations are warranted to determine the ubiquity of miR-29 mediated autophagy 
inhibition across various cancer types, as well as determine if miR-29 family members 
have different impacts on autophagy. 
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Finally, a recent report indicated that autophagy plays a critical role in PSCs as 
well (290). PDAC cells were shown to induce autophagy in PSCs, which in turn 
catabolize their internal components and secrete alanine to further fuel cancer cell 
proliferation (290). In addition to testing the effect of miR-29 on autophagy in other 
cancers, it would be interesting to determine if restoration of miR-29 in activated PSCs 
could also inhibit autophagy. As we observed that miR-29 inhibits the pro-growth effects 
of PSC conditioned media on cancer cells, perhaps miR-29 mediated autophagy 
inhibition in PSCs lend an explanation to our observations. Further studies are necessary 
to determine if this holds true. 
 
5.3 Mechanisms of miR-29 in Pancreatic Cancer Cell Migration Potential 
Metastasis occurs when cancer cells undergo epithelial-mesenchymal transition 
(EMT), a cellular reprogramming event in which epithelial cells revert to a pseudo-stem 
cell state that is characterized by a loss of polarity and increased migratory behavior 
(291).  EMT plays a vital role in normal physiology during development as well as in 
wound healing, but it is also exhibited in cancer metastasis where a subset of tumor cells 
disseminate to distant organ sites beyond the site of origination. As a defining signature 
of Stage IV cancer, metastasis is regarded as a major cause of cancer mortality (292). 
This is largely because by the time a cancer has metastasized, surgical resection is 
typically no longer a viable option, and metastatic tumors are often refractory to 
conventional therapies.  
miR-29 has been well-established to inhibit migration/metastasis in various 
cancers through direct inhibition of a several pro-metastatic targets (112, 293-298) 
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including in pancreatic cancer (156, 157, 296). Consistent with these outcomes, we find 
that miR-29 inhibits migration/invasion in vitro and facilitates mesenchymal-epithelial 
transition (MET), as indicated by an increase in E-cadherin and reduction in Vimentin. 
However, we have not yet identified the exact mechanism by which miR-29 inhibits the 
migratory potential of pancreatic cancer cells.  
Although a few mechanisms have been proposed, all three reports offered 
different hypotheses for which miR-29 target downregulation leads to reduced 
migration/invasion in PDAC (MMP2, MUC1, ITGB1) (156, 157, 296). This is further 
complicated by the fact that a single miRNA may simultaneously regulate a number of 
genes within multiple intracellular networks (107). Many of the current miRNA studies 
rely upon target prediction algorithms. It could be possible that miR-29 mediates these 
effects through all three targets, in combination or through other targets that have yet to 
be discovered. These incongruities demand the need for a better, systematic approach to 
understanding mechanisms in miR-29.  
One potential method to resolving this issue could be accomplished by first 
identifying direct miR-29 targets through quick cross-linking, ligation, and sequencing of 
hybrids (qCLASH), followed by a comprehensive CRISPR-based functional genomic 
screen of target miR-29 binding sites identified in qCLASH. qCLASH is a new technique 
by which direct miRNA binding sites of target transcripts can be detected with a higher 
degree of confidence through crosslinking/Ago-IP in conjunction with ligating the 
miRNA to the target binding site and subjecting it to deep-sequencing (299). Confidence 
in this dataset could be tested by conducting an enrichment analysis for predicted targets 
from algorithms such as Targetscan (72). Once these de novo binding sites have been 
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identified, a custom, pooled CRISPR library can be made, utilizing Cas9 fused to GFP 
(300) with gRNAs designed to delete specific miR-29 binding sites identified via 
qCLASH. Subsequently, stable cells would be collected based on GFP expression, 
transfected with either negative control or miR-29 mimic, and subjected to transwell 
migration assay. Following a 24-hour migration period, the DNA of migrated cells would 
be isolated, subjected to deep-sequencing, and the presence of gRNAs in miR-29 
overexpressing cells but not in control would indicate the most functionally relevant miR-
29 targets. Following validation of the top-ranking candidate genes as proof-of-concept 
for this approach, the experiment could be repeated in a number of other pancreatic 
cancer cell lines to select targets that overlap between the greatest numbers of cell lines. 
This would provide an extensive dataset where the entire miR-29 targetome could be 
functionally tested in a high-throughput and unbiased manner.  
 
5.4 The Need for miR-29 In Vivo Validation 
Although our findings clearly demonstrate miR-29’s anti-fibrotic potential in 
PSCs and tumor suppressor function in cancer cells, much of this work was conducted in 
vitro and requires further validation to see if these findings translate in vivo. We have 
established a method of functionally studying the role of miR-29 in vivo via optimized 
intraductal delivery method of scAAV6, which demonstrated a high degree of 
transduction efficiency. We currently possess an AAV vector that expresses miR-29a 
under a ubiquitous EF1α promoter. Utilizing this parental vector, we will create two 
different rAAV vectors by replacing the EF1α promoter with an α-SMA or PDX-1 
promoter for PSC- and cancer cell-specific expression respectively. We will package 
 160 
rAAV vectors with AAV6 serotype and dose GEMMs of PDAC via intraductal delivery 
to study the functional effects of miR-29 restoration on stromal compartment and cancer 
cells and determine its impact on tumor progression and survival. The results of these in 
vivo studies will provide valuable insights on the role of miR-29 in pancreatic cancer, and 
test its therapeutic potential through a clinically translational surgical delivery method. 
In contrast to the expected outcomes of our studies, the loss of miR-29 was 
recently reported to have no impact on pancreatic acinar carcinoma (301). However, 
these findings should be admonished due to several pitfalls. First, miRNAs regulate gene 
expression in a cell-type-specific manner, and this study employed a whole-body miR-29 
KO which limits the ability to isolate miR-29 function within the model system. As the 
authors conceded, crossing whole-body miR-29 KO mice with viral SV40 T antigen 
driven acinar cancer model is not as physiologically relevant as other more commonly 
used GEMMs of pancreatic cancer (113, 215).  Finally, pancreatic acinar carcinoma 
comprises a small percentage of patients compared to pancreatic ductal adenocarcinoma 
(302). Nevertheless, these incongruities demand the need for further studies to better 
understand these seemingly unexpected results. In contrast to this study, our intraductal 
delivery technique showed limited off-target effects and will provide a more refined 
method of elucidating miR-29 function in specific cell types of PDAC. 
 
5.5 The Pragmatism of miRNA-Based Therapies 
Since the discovery of the first miRNA, the area of miRNA research has rapidly 
expanded and moved beyond basic biology into therapeutic use. Within only the past two 
decades, >2,000 patent documents related to miRNAs have been published (303). Even 
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so, the development of miRNA therapeutics lags behind many other forms of treatment 
including RNAi based drugs (304). Recent setbacks were made when the first miRNA 
based clinical trial that tested the therapeutic effect of miR-34 (MRX34) in cancer was 
halted at Phase I due to immune-related side-effects (305). However, these adverse events 
may have not been due to miR-34 itself, but rather caused by the method of delivery (e.g. 
liposomes) or immunostimulation induced by double-stranded RNA (305, 306).  
Nevertheless, the promise of miRNA-based therapies has remained appealing as 
indicated by the numerous miRNA based therapies that are still actively being pursued 
within the pipelines of several biotech companies (304). In fact, miR-29 mimic, MRG-
201, is currently being tested in Phase I clinical trials via intradermal injection 
(ClinicalTrials.gov; NCT02603224). As new and improved modes of gene delivery are 
being developed and tested (307-309), it may be just a matter of time before additional 
therapeutic delivery methods will be available for miR-29 to be tested in cancer.  
 
5.6 Controversies of miR-29 in Cancer 
 Although miR-29 may seem to show a high degree of promise as a potent tumor 
suppressor, the minority of studies reporting miR-29 as an oncogene are still grounds for 
circumspection and must be strongly taken into consideration. The drastically opposing 
effects of miR-29 reported even within the same cancer types, such as breast cancer (310-
313) and pancreatic cancer (156, 157, 314, 315), is confounding.  
Genomic heterogeneity is a well-known feature of cancer and exists between 
tumors of different patients and is even evident within the same tumor (316). In recent 
years, there has been a paradigm shift towards classifying cancers based on genetics 
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rather than in the context of anatomical location. In fact, Pembrolizumab was the first 
recently FDA approved cancer therapy on the basis of the patients’ tumor gene 
expression profile instead of the cancer’s originating tissue-type. As miRNAs function in 
a context dependent manner (317-320), the discrepancies of miR-29 function and 
alternative mechanisms of action may be due to a lack of contextualizing miR-29 against 
specific genetic backgrounds. Most of the current miR-29-related literature in cancer 
frequently generalizes the function of miR-29 within the framework of organ-based 
stratification without acknowledging the genetic background of the cells and biopsies. 
This may be due to the fact that utilizing a traditional, reductionist approach in biology to 
factor in so many various genetic variables is a daunting, if not impossible, task.  
Recent advancements of high-throughput technologies such as proteomics, next 
generation sequencing, single cell sequencing, and functional genomics has facilitated a 
more refined insight into global gene regulation, as well as provided a more systematic 
approach to testing the function of genes on a large scale. The accumulation of large 
genomic databases (e.g. The Cell Atlas, TCGA, Project Achilles) has allowed for a 
greater degree of resolution in studying the effects of heterogeneity associated with 
cancer. Perhaps utilizing these comprehensive methods of Integrative Omics and Systems 
Biology will provide a more auspicious approach to better understanding miR-29’s 
function in the context of cancer. 
In fact, some systematic studies have already been conducted for miR-29. For 
example, Chris Sander's group analyzed miRNA expression across 10 cancer types in the 
TCGA database to determine commonalities in miRNA-target networks (321). They 
noted that, “miR-29a was generally downregulated… in tumors of most cancer types as 
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compared with representative normal samples.” (321). Other analogous analyses utilizing 
comprehensive approaches find similarly consistent results of miR-29 as a tumor 
suppressor (322, 323). With time, further methodical studies employing these techniques 
in an unbiased fashion will rectify the disputed role of miR-29 as tumor suppressor versus 
tumor promoter.  
 
5.7 Concluding Remarks 
The multifaceted function of miR-29 lends concern to claiming it as a panacea for 
PDAC. The dichotomous role of miR-29 as tumor suppressor versus oncogene may be 
context dependent. However, at the current moment, miR-29 is well-documented as a 
tumor suppressor, with >85% of all miR-29/cancer-related studies demonstrating miR-29 
inhibiting various oncogenes (Figure 1B). It will be of interest to see if future studies that 
investigate the function of miR-29 in a more comprehensive and systematic manner will 
resolve these disputes and elucidate a more refined perspective on miR-29’s role in 
PDAC. In spite of the contrasting reports, our findings clearly demonstrate miR-29 is a 
potent anti-fibrotic agent and tumor suppressor in PDAC. Further follow up studies, as 
proposed in the discussion section, will provide a more thorough understanding of miR-
29’s role in pancreatic tumor-stromal interactions and cancer biology and may serve as 
the foundation for the future use of miR-29 as a novel therapeutic agent for PDAC. 
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